



UNIFORMED SERVICES UNIVERSITY, SCHOOL OF MEDICINE GRADUATE PROGRAMS  
Graduate Education Office (A 1045), 4301 Jones Bridge Road, Bethesda, MD 20814





DISSERTATION APPROVAL FOR THE DOCTORAL DISSERTATION IN THE EMERGING  
INFECTIOUS DISEASES GRADUATE PROGRAM

Title of Dissertation: "Regulation of innate immune responses is required for *S. mansoni* Development"


Name of Candidate: Diana Riner  
Doctor of Philosophy Degree  
January 23, 2013

DISSERTATION AND ABSTRACT APPROVED:

  
DATE: 3/21/13  
Dr. Edward Mitre  
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY  
Committee Chairperson

  
3/25/13  
Dr. Stephen Davies  
DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY  
Dissertation Advisor

  
3/25/13  
Dr. Clifford Snapper  
DEPARTMENT OF PATHOLOGY  
Committee Member

  
3/26/13  
Dr. Thomas Wynn  
Chief Immunopathogenesis section ,NIH  
Committee Member

The author hereby certifies that the use of any copyrighted material in the thesis manuscript entitled:

“Regulation of innate immune responses is required for *Schistosoma mansoni* development”

is appropriately acknowledged and, beyond brief excerpts, is with the permission of the copyright owner.

A handwritten signature in black ink, appearing to read "Diana Riner". The signature is fluid and cursive, with the first name "Diana" and last name "Riner" clearly distinguishable.

Diana Riner

Emerging Infectious Disease Program

Department of Microbiology and Immunology

Uniformed Services University

01/07/2013

## Abstract

Title of Dissertation:

Regulation of innate immune responses is required for *S. mansoni* development

Diana Kathleen Joanna Riner, Doctor of Philosophy, 2013

Thesis directed by:

Stephen J. Davies, BVSc, Ph.D.

Associate Professor, Department of Microbiology and Immunology

Uniformed Services University of the Health Sciences

Helminth blood flukes of the genus *Schistosoma* infect over 200 million people. As a result of host-parasite co-evolution, *S. mansoni* evolved to exploit host immune factors as signals to coordinate its own development. Worms fail to develop normally in RAG<sup>-/-</sup> mice, lacking T and B cells, while development is restored by adoptive transfer of CD4<sup>+</sup> T cells, suggesting that CD4<sup>+</sup> T cells play a central role in regulating parasite development. Recent findings suggest the role of CD4<sup>+</sup> T cells in this process is indirect, being limited to provision of non-cognate T cell help for innate responses which, in turn, facilitate parasite development. In support of this hypothesis, we have found that long-term stimulation of TLR4 by LPS, a pathogen associated molecular pattern (PAMP), in RAG<sup>-/-</sup> mice, in the absence of CD4<sup>+</sup> T cells, also restores worm development, indicating that innate immune

signals are sufficient for parasite development to proceed normally. We have also found that chronic TLR stimulation via other PAMPs that utilize MyD88 dependent signaling, as well as chronic inflammasome signaling were also sufficient to restore worm development in RAG<sup>-/-</sup> mice. Chronic stimulation of both of these pathways resulted in down-regulated pro-inflammatory responses leading us to hypothesize that regulation of innate immune responses are necessary for restoration of *S. mansoni* development. In support of this hypothesis we found blocking TNF- $\alpha$  or administering IL-4 also led to the regulation of pro-inflammatory immune responses that favored parasite development as well. Administering IL-4 to immunodeficient mice also resulted in the establishment of Th2 like immune environment. This suggests that in immunologically intact animals it is the establishment of Th2 responses that promote parasite development. Elucidation of the innate immune signals that control schistosome development could provide leads for the development of new drug targets and vaccine strategies.



**Regulation of innate immune responses is required for *S. mansoni* development**

**By**

**Diana K. Riner**

**Dissertation submitted to the Faculty of the**

**Emerging Infectious Diseases Intradisciplinary Graduate Program of the**

**Uniformed Services University of the Health Sciences**

**F. Edward Hebert School of Medicine**

**In partial fulfillment of the**

**requirements for the degree of**

**Doctor of Philosophy 2013**

## **Acknowledgements**

First and foremost, I would like to acknowledge the guidance and support of my advisor and mentor Dr. Stephen Davies. Stephen is an excellent scientist and has an amazing command of the scientific literature pertaining to parasites and immunology. He also possesses a caring soul and wants the best for his students and inspires his students to strive to achieve their fullest potential. I know that I am a better scientist and a better person for having worked under Dr. Davies and for that I sincerely thank him. Second, I would like to acknowledge Dr. Erika Davies whose project I took over. Thank you for gracious support and advice and thank you for trusting me with your “baby”. I would also like to acknowledge Dr. Mitre, my committee chair, and my committee members Dr. Snapper and Dr. Wynn for their help and guidance. The process to get a PhD has been referred to as a marathon and this is an apt description. I thank my advisor and committee for keeping me on course and not letting me stray, and thank my classmates Paige Sachs, Dawn Weir, Tonia Zangari, Deborah Steffen, and Suman Paul for cheering me on and for their friendship and support. Finally, thank you to my former lab members Dr. Brett Swierczewski Dr. Christine Ferragine and Mr. Sean Maynard for their friendship, support, and trips to McDonalds.

## **Dedication**

I am blessed to come from a long line of strong women. I dedicate this work to my mother Janet Lynn Riner, and my grandmothers Laura Manaci and Joan Riner. From these women I have learned the value of education, hard work, dedication, loyalty, and above all love for family. My mother, who knows me better than I know myself, instilled in all of her children that education was the key to our success and would open doors for us. Grandma Manaci escaped from the extreme poverty of the coal mines and had a life full of struggle and strife yet she never let that steal her goodness or gentle spirit. My Grandma Riner grew up on a farm in southwest Ohio during the depression and remembers having to pluck chickens before school on market day. While she never made me pluck chickens she did pass down to me the same work ethic that was instilled in her and while the farm has long been sold I like to think that its legacy still lives on in her and through her grandchildren.

## Table of Contents

<b>Approval sheet.....</b>	<b>i</b>
<b>Copyright Statement.....</b>	<b>ii</b>
<b>Abstract.....</b>	<b>iii</b>
<b>Title Page.....</b>	<b>v</b>
<b>Acknowledgements.....</b>	<b>vi</b>
<b>Dedication.....</b>	<b>vii</b>
<b>Table of Contents.....</b>	<b>viii</b>
<b>Table of Figures.....</b>	<b>xiv</b>
<b>Chapter 1-General Introduction.....</b>	<b>1</b>
History and Epidemiology of Schistosomes.....	2
History.....	2
Epidemiology of Schistosomiasis.....	3
Lifecycle of Schistosomes.....	3
Disease Pathology Associated with <i>S. mansoni</i> .....	4
Acute Disease.....	4
Chronic Disease.....	5
Treatment.....	6
Vaccine Development.....	7
Immune Response to <i>S. mansoni</i> .....	8
Basic Overview.....	8
Th1 versus Th2 responses during <i>S. mansoni</i> infection: The need for a balanced response.....	9

Shistosomula influence the development of Type 2 responses.....	10
Worms influence development of Type 2 egg responses.....	11
Eggs and regulation.....	11
Immune system modulation of <i>S. mansoni</i> development is not dependent on CD4 <sup>+</sup> T cell recognition of parasite antigen.....	12
<i>S. mansoni</i> development is not restored as a result of antigen specific T cell responses.....	13
Innate immune signals are sufficient for parasite development to proceed normally.....	14
Rationale for specific aims.....	15
General Hypothesis.....	17
Specific Aims.....	17
References.....	20
 <b>Chapter 2- Regulation of pro-inflammatory responses during pre-patent schistosome infection creates an immune environment permissive for parasite development...27</b>	
Abstract.....	28
Introduction.....	29
Materials and Methods.....	31
Ethics statement.....	31
Experimental Mice.....	31
Parasite parameters.....	31
Measuring areas of liver inflammation and coagulative necrosis.....	32
Acetaminophen (AAP) and D-(+)-galactosamine hydrochloride	

(GalN) treatment.....	33
Monosodium urate (MSU), Alum, LPS, and Poly-IC treatment.....	33
Anti-TNF- $\alpha$ treatment.....	34
IL-4 complex treatment.....	34
RNA isolation, purification, and Real time PCR.....	34
Statistical analysis.....	35
Results.....	37
<i>Pre-patent S. mansoni infection fails to induce liver inflammation         and necrosis in immunodeficient mice.....</i>	37
<i>Endogenous danger-associated molecular patterns restore S. mansoni         development in immunodeficient mice.....</i>	38
<i>Parasite development correlates with regulation of IL-1<math>\beta</math> transcription.....</i>	39
<i>Chronic innate immune stimulation with LPS or MSU results in         downregulation of proinflammatory signals.....</i>	40
<i>Parasites fail to develop when proinflammatory gene transcription         is sustained.....</i>	41
<i>TNF blockade restores parasite development in immunodeficient mice.....</i>	42
<i>Administration of IL-4 complex restores parasite development         in immunodeficient mice.....</i>	43
Discussion.....	46
References.....	54

<b>Chapter 3 Restoration of <i>S mansoni</i> development in immunodeficient worms by chronic TLR stimulation is dependent upon MyD88 signaling.....</b>	<b>75</b>
Abstract.....	76
Introduction.....	77
Materials and Methods.....	79
Ethics statement.....	79
Experimental Mice.....	79
Parasite parameters.....	79
TLR stimulation.....	80
RNA isolation, purification, and Real time PCR.....	80
Statistical analysis.....	81
Results.....	82
<i>TLR1/2 stimulation by PAM3CSK4 restores parasite development in immunodeficient mice.....</i>	<i>82</i>
<i>Restoration of parasite development in immunodeficient mice is specifically associated with MyD88-dependent regulation and not TLR location.....</i>	<i>83</i>
<i>Transcriptional changes associated with restoration or failure of parasite development.....</i>	<i>85</i>
<i>Lack of correlation between presence of parasite eggs and liver cytokine transcription.....</i>	<i>86</i>
Discussion.....	89
References.....	95

<b>Chapter 4- IL-1 signaling is not required for innate immune regulation after chronic LPS or alum stimulation.....</b>	<b>107</b>
Introduction.....	108
Materials and Methods.....	110
Ethics statement.....	110
Experimental Mice.....	110
Parasite parameters.....	110
Alum and LPS treatment.....	111
Anti-TNF treatment.....	111
Anti-TNF and LPS treatment.....	112
RNA isolation, purification, and Real time PCR.....	112
Statistical analysis.....	113
Results.....	114
<i>IL-1 signaling is not required for restoration of parasite development by chronic TLR or inflammasome stimulation.....</i>	<i>114</i>
<i>Blockade of TNF in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice further stunts parasite development.....</i>	<i>115</i>
<i>Blockade of TNF in RAG<sup>-/-</sup> mice restores parasite development similar to that of LPS administration.....</i>	<i>115</i>
<i>Cytokine transcription profiles differ in RAG<sup>-/-</sup> and RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice treated with anti-TNF.....</i>	<i>116</i>
Discussion.....	118



References.....	121
<b>Chapter 5 Summary and Future Directions.....</b>	<b>133</b>
Dissertation Summary.....	134
Timeline for <i>S. mansoni</i> development in the context of the host immune response.....	135
Immunological Redundancy in Parasite Development.....	140
Host cells required for parasite development.....	142
Concluding Remarks.....	147
References.....	148

## Table of Figures

Figure 1. Early <i>S. mansoni</i> infection fails to induce liver inflammation and coagulative necrosis in RAG <sup>-/-</sup> mice.....	59
Figure 2. Inducing hepatocyte death and inflammasome activation facilitates <i>S. mansoni</i> development in RAG <sup>-/-</sup> mice.....	61
Figure 3. <i>S. mansoni</i> development occurs in the context of down-regulated IL-1 $\beta$ expression.....	63
Figure 4. Chronic TLR-4 or NALP3 inflammasome activation results in the regulation of pro-inflammatory cytokine gene expression.....	65
Figure 5. Chronic TLR-3 signaling results in the upregulation of proinflammatory gene expression and fails to restore <i>S. mansoni</i> development in immunodeficient mice .....	67
Figure 6. Inducing regulation of pro-inflammatory cytokines via blockade of TNF restores <i>S. mansoni</i> development in RAG <sup>-/-</sup> mice.....	69
Figure 7. IL-4 promotes a Th2-like environment that facilitates <i>S. mansoni</i> development in RAG <sup>-/-</sup> mice. ....	71
Figure 8. Chronic stimulation of TLR2 with bacterial Pam3CSK4 facilitates <i>S. mansoni</i> development in RAG <sup>-/-</sup> mice and results in regulation of pro-inflammatory cytokine gene expression.....	99
Figure 9. Restoration of parasite development in RAG <sup>-/-</sup> mice after chronic TLR stimulation is MyD88 dependent.....	101
Figure 10. Chronic TLR-4 signaling via LPS results in downregulated	

pro-inflammatory gene expression while chronic TLR-3 signaling via poly I:C results in the up-regulation of pro-inflammatory gene expression.....	103
Figure 11. Chronic TLR signaling does not result in the down-regulation of liver TNF mRNA transcription after egg deposition begins in immunodeficient Mice.....	105
Figure 12. IL-1 receptor signaling is not required for restoration of parasite development in immunodeficient mice after chronic inflammasome or TLR stimulation.....	123
Figure 13. Neither TNF nor IL-1R signaling are required for restoration of parasite development in $RAG^{-/-}IL-1R^{-/-}$ mice after chronic TLR stimulation.....	125
<u>Figure 14.</u> TNF blockade alone is sufficient for restoration of parasite development in $RAG^{-/-}$ mice after chronic TLR stimulation.....	127
Figure 15. TNF blockade does not result in changes to splenic inflammatory cytokine gene expression in $RAG^{-/-}IL-1R^{-/-}$ mice.....	129
Figure 16. TNF blockade results in downregulated splenic IL-1 receptor antagonist (IL-1RA) in $RAG^{-/-}$ mice.....	131
Figure 17. Potential model highlighting early <i>S. mansoni</i> and host immune interactions during prepatent infection.....	138
Figure 18. Chronic stimulation of TLR4 with bacterial LPS facilitates <i>S. mansoni</i> Development in $\gamma c^{-/-}RAG^{-/-}$ mice.....	145
Supplemental Figure 1. Long term MSU administration results in the regulation of pro-inflammatory responses. ....	73

## **Chapter 1**

### **General Information**

## History and Epidemiology of Schistosomes

### History

Schistosomiasis is the name given to diseases caused by parasitic blood flukes of the genus *Schistosoma*. While there are numerous species of schistosomes, only 5 are considered to be of relevance for human infection and they are *S. mansoni*, *S. haematobium*, *S. japonicum*, *S. mekongi*, and *S. intercalatum* [1]. Schistosomes are responsible for two forms of disease - urinary schistosomiasis, whose causative agent is *S. haematobium*, and hepatosplenic schistosomiasis, whose causative agents are *S. mansoni*, *S. japonicum*, *S. mekongi*, and *S. intercalatum* [2]. The three most medically relevant species of schistosomes are *S. mansoni*, *S. haematobium*, *S. japonicum* [2]. Eggs for *S. haematobium* have been found in Egyptian mummies, as have fossil records for its snail intermediate host [3], and the first definitive reports for this disease in Egypt were reported by a French army surgeon during Napoleon's Egyptian campaign in 1798 [1,3].

Theodor Bilharz is credited with discovering *Schistosoma* in 1851, although he named what is now *S. haematobium* as *Distonum haematobium* and credited this species as producing both lateral and terminal spined eggs [1,4]. In 1902, Patrick Mason suggested that the eggs belonged to two distinct schistosomes species, and in 1907 Sambon suggesting that lateral-spined eggs should be called *S. mansoni* [1]. Finally in 1915, R.T. Leiper showed these eggs were indeed from two different species of worms, as they required different snail intermediate hosts [1,4,5]. The first report of *S. japonicum* in the modern literature was a description of the ancient disease Katayama fever by Dairo Fujii in 1847 in Japan, with the snail intermediate host being reported in that country in

1913 [5].

### Epidemiology of Schistosomiasis

At present, over 200 million people are infected with schistosomiasis [2,6,7], another approximately 700 million people are at risk of acquiring the infection [8] and the disease is endemic in over 70 countries [7]. However, an estimated 93% of cases worldwide occur in Sub-Saharan Africa, with *S. mansoni* infections responsible for one-third of that number and *S. haematobium* responsible for the other two-thirds [9,10]. After infection, schistosomes are able to survive inside the host for many years despite robust host immune responses [11].

### **Lifecycle of *S. mansoni***

The lifecycle of *S. mansoni* is complicated and involves a definitive mammalian host and a freshwater snail intermediate host of the genus *Biomphalaria*. Adult worms live in the mesenteric venules of their mammalian host, where the females can produce hundreds of eggs per day. These eggs cross through the bowel wall and are excreted in feces. Upon exposure to water, ciliated miracidia emerge from the eggs, penetrate snails of the genus *Biomphalaria*, and develop into cercariae. Cercariae exit the snail host approximately 4 weeks later to find a mammalian host in order to complete development. Humans become infected via contact with water containing cercariae. The cercariae penetrate through the skin, access the bloodstream, travel to the lungs, and then migrate to the liver. At approximately 4 to 6 weeks post infection, female and male worms form

pairs, and migrate to the mesenteric venules, where eggs are released to continue the cycle anew [1,2].

### **Disease pathology associated with *S. mansoni***

#### **Acute Disease**

Infection with *S. mansoni* begins with the penetration of skin by cercariae and can result in a cercarial dermatitis, characterized by formation of a maculopapular rash at the site of penetration as soon as an hour after exposure. This pathology is similar to swimmers itch but less severe [12-15]. Exposure to nonhuman schistosomes, whose hosts are usually birds, results in swimmer's itch that manifests as an intense pruritic dermatitis in response to the dying cercariae [12,14]. The acute phase of *S. mansoni* infection is thought to start around 4 to 6 week post infection (p.i.) and coincides with the beginning of egg laying [11,12,14], although symptoms have been reported as soon as 11 to 21 days post exposure to water containing cercariae [13,16]. Symptoms include fever, malaise, nausea, diarrhea, non-productive cough, headache, edema, and eosinophilia. This is sometimes referred to as Katayama syndrome and is thought to be an immune-mediated hypersensitivity reaction against the migrating parasite or the first egg depositions [2,15,17-19]. Occasionally, acute infection can result in neurological, pulmonary, cardiac, hepatic, or intestinal sequelae. Acute disease usually manifests in individuals experiencing their first infection upon visiting an endemic area [12-14]. Acute disease is not commonly reported in individuals living in endemic areas. Reasons for this include underreporting, due to inadequate healthcare systems, and the early age at

which the primary infection occurs, as individuals in endemic areas have often acquired their first infection by age two [20]. Protection from acute disease is also thought to occur via exposure to schistosome antigens in utero or through breast milk, resulting in an immune response primed to respond to eggs [11,21].

### Chronic disease

Chronic schistosomiasis develops in the months to years following the initial infection and repeated re-infections. Pathology can range from mild intestinal and hepatointestinal changes to severe hepatosplenic pathology [12]. Pathology is caused by parasite eggs that become trapped in the liver, intestinal wall and other tissues [2,22,23].

Granulomas form around the trapped eggs and help control the disease by preventing tissue damage from toxins produced by the eggs [24,25]. However, this granulomatous response can result in fibrosis, leading to intestinal and liver pathology [2,26].

Symptoms for the milder intestinal form of the disease include diarrhea, haematochezia (bloody stool), constipation, and gastric and iliac pain. More severe complications can include colonic stenosis, rectal stenosis, or polyp formation [14,17]. Granuloma

formation in the liver can result in excessive deposition of collagen and other extracellular matrix components, leading to periportal liver fibrosis that is sometimes referred to as clay pipe stem fibrosis [2,14,17], and resulting in the occlusion of portal veins[15] that give the liver a “turtle back” appearance [23]. Complications from excessive fibrosis include hepatomegaly, splenomegaly, portal hypertension, ascites, portocaval shunting, and gastrointestinal varices [2,14,15]. Variceal bleeding can result in anemia due to blood loss and severe sudden hemorrhage can result in death [15]. Other



complications from chronic schistosomiasis include pulmonary hypertension [14,27] neuroschistosomiasis, glomerulonephritis, growth retardation in children, as well as possible cognitive and memory impairment in children [2,14,15,17].

## **Treatment**

Praziquantel is the only approved therapy shown to be effective against all species of schistosomes. However, praziquantel is only lethal to adult worms and does not provide protection from juvenile worms or from re-infection. During acute disease, steroids such as prednisone are often used in conjunction with praziquantel to provide relief for symptoms, as treatment with praziquantel alone is often not sufficient [19,28]. Schistosome resistance to praziquantel has also been demonstrated in laboratory settings [29,30] as well as from *S. mansoni* isolates recovered from Kenyan patients [31]. In 2008 the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) program was enacted via funding from the Bill and Melinda Gates foundation in order to combat schistosomiasis using a variety of strategies, including mass praziquantel administration in numerous counties across Africa (<http://score.uga.edu/>). However, while mass praziquantel administration is helping to reduce the numbers of infections in humans, the disease is not being eradicated in the areas where mass treatments are occurring [6,32,33], raising the concern of rebound mortality if control programs are halted [34]. While important for killing worms and preventing exacerbation of chronic disease, praziquantel will not reverse the chronic pathology that has already occurred. Together these findings highlight why the development of new therapies and vaccines for

treatment and prevention of schistosomiasis is an urgent priority.

### **Vaccine development**

Development of a successful vaccine to combat schistosomiasis has been an unrealized goal in the schistosomiasis community for decades. As natural infection does not eventually confer sterile immunity, two major challenges are (i) how to define protective immunity in humans and (ii) how to engineer a vaccine that generates an immune response to exceed that which is induced by natural infection [35,36]. In light of this, there has been a paradigm shift in regards to schistosome vaccines, from the idea of achieving sterile immunity as is generally the goal of bacterial and viral vaccine candidates, to finding vaccine candidates that decrease worm burdens or fecundity, in the hope of decreasing disease severity when used in combination with chemotherapy [35,37,38]. This is thought to be an achievable goal, as irradiated cercarial vaccines, while not a viable option for human vaccinations, have been shown to confer up to 80% protection in various animal models [39-42] and numerous schistosomal antigens can achieve at least 30% protection [36]. Two promising vaccine candidates are the protein based vaccine candidate fatty acid-binding protein (FABP)-14 (SM14), which has been approved for a phase 1 clinical trial [43], and a DNA-based or recombinant protein vaccine candidate Sm-p80, a protein involved in surface membrane biogenesis [44-46]. Both of these vaccine candidates result in a Th1 biased immune response [21,44-46].

It remains to be determined if Th1 biased immune responses are optimal for generating protection to challenge infections, or if a Th2 biased response would result in

better protection, as the sterile immunity that is seen in rats (a naturally non-permissive host) is associated with the production of IL-4, IL-5 and IL-13 [47]. Sixty percent protection was obtained when mice were vaccinated with the schistosome excretory/secretory (ES) antigens rSG3PDH and TPX MAP along with thymic stromal lymphopoietin (TSLP), a cytokine whose production amplifies Th2 responses [47]. Besides determining the best vaccine candidates to move to clinical trials, challenges remain in determining dosage schedules in coordination with drug treatment, as well as determining measures for reduction of morbidity and mortality to show vaccine efficacy, since sterile immunity is not an achievable aim [35].

### **Immune response to *S. mansoni***

#### Basic overview

The immune response to *S. mansoni* occurs in two waves. The first is a T helper 1 response ( $T_H1$ ) in reaction to the parasite. During the acute phase, high levels of tumor necrosis factor (TNF) can be measured in the plasma of infected patients and peripheral blood mononuclear cells (PMBCs) produce high levels of TNF, interleukin-1 (IL-1), and IL-6 in reaction to worm antigen [11,16,20]. However, egg production results in a switch from a  $T_H1$  response to a strong T helper 2 response ( $T_H2$ ), characterized by the production of IL-4 and IL-5 [48,49]. Granuloma formation around the eggs is the key to host survival [50,51], with lack of IL-4 leading to a Th1 pro-inflammatory response and resulting in severe disease and early mortality [25,52-55]. Overall, a protective immune response to schistosomes is characterized by an early Th1 response, with production of

IL-2, IFN- $\gamma$ , and TNF- $\alpha$  before egg deposition, then by a switch to a Th2 response, with production of IL-4, IL-5, IL-10, and IL-13 after egg deposition, and then followed by a regulatory response characterized by IL-10 production and downmodulated T-cell responses [56].

Th1 versus Th2 responses during *S. mansoni* infection: The need for a balanced response

In mouse models, protection induced by experimental vaccines correlate with strong Th1 responses directed against the schistosomula stage in the skin and lung [57,58]. However, severe human hepatosplenic disease also correlates with strong Th1 responses directed towards the eggs [59,60]. By 7 to 8 weeks post infection, mouse strains such as C3H or CBA are designated high pathology strains, due to increased parenchymal inflammation, larger poorly circumscribed granulomas and increased splenomegaly. In contrast, low pathology mouse strains such as BL/6 and BALB/c show little parenchymal inflammation, smaller well circumscribed granulomas and more moderate splenomegaly [56]. The very different responses seen in these mouse models can be attributed to CD4<sup>+</sup> T cell responses to egg antigens, with Th1 cytokine production predominating in the high pathology mouse strains [61,62]. Lack of IL-4 during *S. mansoni* infection leads to a Th1 pro-inflammatory response and results in severe disease and early mortality [25,52-55]. IL-10 is critical for balancing Th1 versus Th2 responses towards parasite eggs, as IL-10 knockout mice develop a nonpolarized Th1/Th2 immune response that resulted in increased egg granuloma size [54,63]. IL-10/IL-4 deficient mice develop a polarized Th1 response that results in 100% mortality by nine weeks p.i. due in

part to hepatotoxicity[54]. On the other hand IL-10/IL-12 deficient mice, while surviving past week nine p.i., suffered from a progressive wasting disease due to increased granuloma size and fibrosis - a result of a polarized Th2 response characterized by high levels of IL-4 and IL-13 that led to significant mortality in the chronic stages of infection [54]. The increased fibrosis and mortality in these animals is due to IL-13 [53], highlighting the mechanisms by which Th2 responses can be detrimental to the host during chronic infection and underscoring the importance of a balanced immune response.

#### Shistosomula influence the development of Type 2 responses

While penetration and invasion of the skin by *S. mansoni* results in upregulation of pro-inflammatory signals, including TNF [64,65], these responses are short lived, with the parasite utilizing excretory/secretory (ES) molecules to modulate initial immune responses. Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and Prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) are two well characterized ES components [65-68] whose production leads to decreased inflammatory cell recruitment and delayed immune responses in the skin after infection. *S. mansoni* PGE<sub>2</sub> mediates its effects by inducing human keratinocytes to produce both PGE<sub>2</sub> and IL-10 [66]. *S. mansoni* PGD<sub>2</sub> mediates its effects by the inhibition of Langerhans cell (LC) migration out of the skin. Other ES products have similar effects, such as inducing apoptosis of T-cells [69] or inhibiting TLR signaling [70]. These early immune modulations by the parasite have a profound effect on parasite survival, as demonstrated by studies of irradiated cercarial vaccine. Irradiated cercariae have delayed migration out of the skin and are unable to migrate out of the lungs [71,72]. The immune response

generated against them also differs from that of normal cercariae, being predominantly Th1 driven and characterized by IFN- $\gamma$  production by T-cells [58,73-75] and IL-12 production by antigen presenting cells [57,76]. Irradiated cercariae based vaccination can confer protection ranging from 60 to 90% [41,42,58].

### Worms influence development of Type 2 egg responses

While egg antigens are a critical component in the generation of protective Th2 responses, the early immune response to the developing worm also plays a vital role in the shaping of this immune response. The generation of these Th2 responses has been shown to occur early in *S. mansoni* infection, before the deposition of eggs, and is characterized by the production of IL-4 in response to worm antigen [77,78].

Furthermore, it has been demonstrated that the immune response must first be primed by the developing worms in order for proper Th2 granuloma formation to occur, and that when eggs are injected into naïve animals, the granulomas that form in the liver are much smaller and more abscess-like in appearance [79]. Taken together, these data highlight the importance of immune priming by worm antigens before the appearance of eggs.

### Eggs and regulation

Macrophages are of critical importance in the regulation of excessive egg-induced inflammation. Macrophages are broadly defined as either being classically activated by IFN- $\gamma$  (M1), or alternatively activated by IL-4 and IL-13 (M2) [80]. M2 macrophages are

characterized by the expression of YM1, Fizz1 (also known as RELM- $\alpha$ ), and arginase 1 [81,82]. The lack AAMs during acute infection is lethal, as was shown when mice engineered to have macrophages lacking IL-4R $\alpha$  were infected with *S.mansoni* [83]. Lethality was associated with excessive Th1 responses, resulting in impaired excretion of eggs and leading to increased intestinal pathology and sepsis [83]. Excessive Th2 responses to eggs, on the other hand, are also pathogenic. Deletion of the arginase 1 gene from macrophages results in increased Th2-driven fibrosis during experimental *S. mansoni* infection, highlighting the role of AAMs in not only mediating Th2 inflammation but also in regulating it [84].

### **Immune system modulation of *S. mansoni* development is dependent on**

#### **CD4<sup>+</sup> T cells**

*S. mansoni*, like many helminths, is able to survive in the human host over long periods of time. The first evidence that immune responses were important in schistosome development came from the administration of corticosteroids during early *S. mansoni* infection in 1957. The author found that administering cortisone acetate resulted in a decreased worm burden [85] in mice receiving the drug therapy. These results were confirmed in 1960 by Weinmann and Hunter, with the authors observing that for administration of cortisone acetate to have an impact on worm burden, it needed to be administered early in infection, as administration at the start of the fourth and fifth weeks of infection had no impact on worm burden [86]. Later, it was shown that the mechanism by which corticosteroids exerted their effects was by immunosuppression and not by

direct toxicity to the worms. These authors also reported that T-cell depletion via thymectomy resulted in a reduced worm burden and resulted in delays in oviposition by the parasites [87,88]. The importance of T cell responses in facilitating *S. mansoni* life cycle completion was also shown by the dependence of the parasite on T cell driven granulomatous inflammation for the excretion of parasite eggs, with the authors suggesting that *S. mansoni* was utilizing the definitive host's immune responses in order to continue its own transmission [87]. Davies (2001) went on to demonstrate that *S. mansoni*, in order to complete development, needed immune signals from its mammalian host. Worms isolated from recombination activating gene deficient (RAG<sup>-/-</sup>) C57BL/6 mice, lacking T and B cells [89], were smaller, did not form as many pairs, and had severely impaired egg production. Worm development could be restored in RAG<sup>-/-</sup> mice by reconstitution with CD4<sup>+</sup> T-cells. Reconstitution with both CD8<sup>+</sup> and CD19<sup>+</sup> B cells failed to restore worm development [90]. Additionally, the need for CD4<sup>+</sup> T cells in order to complete development is evolutionarily conserved among the three medically important species of schistosomes [91].

### ***S. mansoni* development is not restored as a result of antigen specific**

#### **CD4<sup>+</sup> T cell responses**

Restoration of worm development is not due to schistosome antigen-mediated T cell activation. Worm development was normal in both Bcl10<sup>-</sup>deficient and Protein kinase C  $\theta$  (PKC $\theta$ ) -deficient mice that possessed T cells incapable of responding to antigen via MHC presentation. In addition, *S. mansoni*-infected transgenic RAG<sup>-/-</sup> mice



with CD4<sup>+</sup> T cell populations specific for single irrelevant antigens (either to chicken ovalbumin (OVA) or pigeon cytochrome C (PCC)), and therefore incapable of responding to schistosome antigen, also exhibited at least partial restoration of worm development [92]. These results suggested that the role of naïve T cells in parasite development was an indirect one and did not involve direct recognition of the parasite. In support of this idea, Lamb demonstrated that there were profound differences in mononuclear phagocyte populations between RAG<sup>-/-</sup> and RAG<sup>-/-</sup> OT-II mice. Possession of naïve T-cells bearing irrelevant TCRs by RAG<sup>-/-</sup> OT-II mice resulted in alteration of mononuclear phagocyte development and promoted a more mature phenotype when compared to RAG<sup>-/-</sup> mice [92].

### **Innate immune signals are sufficient for parasite development to proceed normally**

As parasite development in RAG<sup>-/-</sup>OT-II mice correlated with steady state changes in mononuclear phagocyte development, Lamb hypothesized that direct stimulation of the innate system in RAG<sup>-/-</sup> mice during prepatent infection would restore worm development in those animals. Indeed, she found that administration of LPS, a pathogen associated molecular pattern (PAMP) and toll-like receptor 4 (TLR)-4 ligand [93], to RAG<sup>-/-</sup> mice restored worm development in the absence of CD4<sup>+</sup> T cells [92]. These results raised two important questions that formed the basis of this thesis research. First, we wished to answer the question of how innate immune responses were activated during the course of a natural schistosome infection, in order to provide conditions appropriate for schistosome development. Second, we wished to determine what types of

innate responses and immune factors were required for parasite development to occur.

### **Rationale for Specific Aims**

Innate immune responses are a broad category of responses involving a variety of cell types, pattern-recognition receptors, and signaling pathways. As these categories of responses are so broad, we decided to first focus on LPS and TLR4 signaling, as these had been shown to promote parasite development in  $RAG^{-/-}$  mice [92]. TLR4 is unique amongst TLRs in that it utilizes both MyD88 and TRIF dependent signaling [94]. we therefore sought to determine which of these pathways was implicated in the restoration of parasite development. Signaling through the MyD88 dependent pathway results in the production of inflammatory cytokines. Signaling via TRIF, results in the expression of IFN-inducible genes leading to the production of type 1 interferons [95]. Determination of the signal adaptor molecules necessary for restoration of worm growth by TLR signaling could clarify which inflammatory molecules are important in worm development. We also wanted to determine if other TLR ligands that shared similar signaling pathways to TLR4 could also restore parasite development in  $RAG^{-/-}$  mice. Signaling pathways activated via cell surface or endosomal TLR ligation by bacterial, viral, yeast, or protozoan PAMPs are well characterized in the literature and individual PAMP/TLR interactions result in distinct cytokine profiles [95-97]. Determining other PAMP/TLR interactions capable of restoring parasite develop would thus assist in clarifying the type of innate inflammatory responses conducive to parasite development.

Bacterial, viral, protozoan, or yeast PAMPs typically would not be present in high

enough quantities to facilitate schistosome development during a normal infection. Furthermore while schistosome egg antigens have been shown to activate TLR signaling, for example lysophosphatidylserine activates TLR2 [98] and lacto-N-fucopentaose III activates TLR4 [99], these antigens would also not be present during parasite development. *S. mansoni* 0-to-3-h released larval preparation (0-3hRP) has been shown to stimulate cytokine production by TLR-4 dependent mechanisms, but no specific antigen in the preparation was directly implicated as a TLR4 ligand. The authors speculated that the antigen involved was likely a glycan [100]. Therefore while TLR activation by schistosome antigens is possible, other mechanisms could be responsible for innate immune activation during schistosome infection. An obvious mechanism by which schistosomes can activate innate immune responses is via the tissue damage that occurs as a result of the miratory behavior of the developing parasites [101]. Development of the parasites in portal venules results in liver inflammation and coagulative necrosis before the deposition of eggs begins [102,103]. Necrotic cell death results in the release of damage associated molecular patterns (DAMPs) [104] and robust innate immune responses [105]. Release of DAMPS such as ATP and monosodium urate (MSU) from injured or dying cells results in the activation of the Nalp3 inflammasome, followed by the cleavage of pro-IL-1 $\beta$  to IL-1 $\beta$  by Caspase-1 [106,107]. Schistosome egg antigens have been shown to interact with dectin-2, resulting in Nalp3 activation and release of IL-1 $\beta$  [108] raising the possibility that worm antigens might do the same. Furthermore, malarial hemozoin has been shown in vivo to activate the Nalp3 inflammasome. Schistosomes also release hemozoin as a by-product of red blood cell digestion [109,110] and this could possibly result in Nalp3 inflammasome activation as well, making

inflammasome activation and IL-1 signaling attractive candidates for early innate immune activation.

### **General Hypothesis**

*S. mansoni* development in the definitive mammalian host requires activation of the innate immune response.

### **Specific Aims**

#### **Specific Aim I**

We hypothesize that PAMP/PRR signaling provides an environment permissive to schistosome development.

Aim I: Determine the signaling pathway by which TLR engagement restores *S. mansoni* development in RAG<sup>-/-</sup> mice.

Sub aim 1: Determine if chronic administration of bacterial or viral PAMPs will restore *S. mansoni* development in RAG<sup>-/-</sup> mice.

Sub aim 2: Determine if chronic cell surface or intracellular TLR signaling will restore *S. mansoni* development in RAG<sup>-/-</sup> mice.

Sub aim 3: Determine if Myd88- or TRIF-dependent signaling will restore *S. mansoni*

development in RAG<sup>-/-</sup> mice.

## Specific aim II

We hypothesize that inflammasome signaling induced in response to tissue injury creates an environment permissive to parasite development.

Aim 2: Determine if danger associated molecular patterns (DAMPs), are important for the restoration of *S. mansoni* development in RAG<sup>-/-</sup> mice.

Sub-aim 1: Characterize early hepatocyte cell death after infection with *S. mansoni* in wild type and RAG<sup>-/-</sup> mice.

Sub-aim 2: To induce hepatocyte death in *S. mansoni* infected RAG<sup>-/-</sup> mice during prepatent infection and examine the role of DAMPS in parasite development.

Sub-aim 3: Administer exogenous DAMPs during *S. mansoni* infection in RAG<sup>-/-</sup> mice and examine the role of DAMPS in parasite development.

## Specific Aim III

We hypothesize IL-1/IL-1R signaling is a critical contributor to the permissive environment necessary for schistosome development.

Aim 3: Determine role of IL-1/IL-1R signaling in restoration of *S. mansoni* development

in immunodeficient mice.

Sub-aim 1: Breed RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice in order to determine the role IL-1R signaling plays in restoration of parasite development.

Sub-aim 2: Examine the role of IL-1 $\beta$  and TNF- $\alpha$  in restoration of parasite development in immunodeficient mice.

## References

1. Sandbach FR (1976) The history of schistosomiasis research and policy for its control. *Med Hist* 20: 259-275.
2. Gryseels B, Polman K, Clerinx J, Kestens L (2006) Human schistosomiasis. *The Lancet* 368: 1106-1118.
3. Kloos H, David, R. (2002) The Paleoepidemiology of Schistosomiasis in Ancient Egypt. *Research in Human Ecology* 9: 14-25.
4. Lotfy WM (2009) Human schistosomiasis in egypt: Historical review, assessments of the current picture and prediction of the future trends. *journal of the medical research institute* 30: 1-7.
5. Cox FE (2002) History of human parasitology. *Clin Microbiol Rev* 15: 595-612.
6. King CH, Olbrych SK, Soon M, Singer ME, Carter J, et al. (2011) Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. *PLoS Negl Trop Dis* 5: e1321.
7. Chitsulo L, Engels D, Montresor A, Savioli L (2000) The global status of schistosomiasis and its control. *Acta Trop* 77: 41-51.
8. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis* 6: 411-425.
9. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, et al. (2003) Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop* 86: 125-139.
10. Hotez PJ, Kamath A (2009) Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. *PLoS Negl Trop Dis* 3: e412.
11. Pearce EJ, MacDonald AS (2002) The immunobiology of schistosomiasis. *Nature Reviews Immunology* 2: 499-511.
12. Boros DL (1989) Immunopathology of *Schistosoma mansoni* infection. *Clin Microbiol Rev* 2: 250-269.
13. Enk MJ, Amorim A, Schall VT (2003) Acute schistosomiasis outbreak in the metropolitan area of Belo Horizonte, Minas Gerais: alert about the risk of unnoticed transmission increased by growing rural tourism. *Mem Inst Oswaldo Cruz* 98: 745-750.
14. Gray DJ, Ross AG, Li YS, McManus DP (2011) Diagnosis and management of schistosomiasis. *BMJ* 342: d2651.
15. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, et al. (2009) Immunopathogenesis of human schistosomiasis. *Parasite Immunol* 31: 163-176.
16. de Jesus AR, Silva A, Santana LB, Magalhaes A, de Jesus AA, et al. (2002) Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. *J Infect Dis* 185: 98-105.
17. Ross AG, Bartley PB, Sleight AC, Olds GR, Li Y, et al. (2002) Schistosomiasis. *N Engl J Med* 346: 1212-1220.
18. Ross AG, Vickers D, Olds GR, Shah SM, McManus DP (2007) Katayama syndrome. *Lancet Infect Dis* 7: 218-224.

19. Rabello A (1995) Acute human schistosomiasis mansoni. *Mem Inst Oswaldo Cruz* 90: 277-280.
20. Caldas IR, Campi-Azevedo AC, Oliveira LF, Silveira AM, Oliveira RC, et al. (2008) Human schistosomiasis mansoni: immune responses during acute and chronic phases of the infection. *Acta Trop* 108: 109-117.
21. Brito CF, Caldas IR, Coura Filho P, Correa-Oliveira R, Oliveira SC (2000) CD4+ T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-gamma and tumour necrosis factor-alpha in response to the recombinant 14KDA *Schistosoma mansoni* fatty acid-binding protein. *Scand J Immunol* 51: 595-601.
22. Pearce EJ (2005) Priming of the immune response by schistosome eggs. *Parasite Immunol* 27: 265-270.
23. Manzella A, Ohtomo K, Monzawa S, Lim JH (2008) Schistosomiasis of the liver. *Abdom Imaging* 33: 144-150.
24. Davies SJ, Lim KC, Blank RB, Kim JH, Lucas KD, et al. (2004) Involvement of TNF in limiting liver pathology and promoting parasite survival during schistosome infection. *Int J Parasitol* 34: 27-36.
25. Brunet LR, Finkelman FD, Cheever AW, Kopf MA, Pearce EJ (1997) IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis. *J Immunol* 159: 777-785.
26. Caldas IR, Campi-Azevedo AC, Oliveira LFA, Silveira AMS, Oliveira RC, et al. (2008) Human schistosomiasis mansoni: Immune responses during acute and chronic phases of the infection. *Acta Trop Suppl* 108: 109-117.
27. Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM (2010) Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. *Chest* 137: 20S-29S.
28. Lambertucci JR (1993) Acute schistosomiasis: clinical, diagnostic and therapeutic features. *Rev Inst Med Trop Sao Paulo* 35: 399-404.
29. Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. *Curr Opin Infect Dis* 21: 659-667.
30. Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of *Schistosoma mansoni* to praziquantel: is there a problem? *Trans R Soc Trop Med Hyg* 96: 465-469.
31. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, et al. (2009) Reduced Susceptibility to Praziquantel among Naturally Occurring Kenyan Isolates of *Schistosoma mansoni*. *PLoS Negl Trop Dis* 3: e504.
32. Hodges MH, Dada N, Warmesley A, Paye J, Bangura MM, et al. (2012) Mass drug administration significantly reduces infection of *Schistosoma mansoni* and hookworm in school children in the national control program in Sierra Leone. *BMC Infect Dis* 12: 16.
33. Landoure A, Dembele R, Goita S, Kane M, Tuinsma M, et al. (2012) Significantly reduced intensity of infection but persistent prevalence of schistosomiasis in a highly endemic region in Mali after repeated treatment. *PLoS Negl Trop Dis* 6: e1774.



34. Daffalla AA, Fenwick A (1982) Resurgence of *Schistosoma mansoni* and *Schistosoma haematobium* after the end of a 4-year control programme against *S. mansoni*. *Trans R Soc Trop Med Hyg* 76: 701-702.
35. Siddiqui AA, Siddiqui BA, Ganley-Leal L (2011) Schistosomiasis vaccines. *Hum Vaccin* 7: 1192-1197.
36. Wilson RA, Coulson PS (2006) Schistosome vaccines: a critical appraisal. *Mem Inst Oswaldo Cruz* 101 Suppl 1: 13-20.
37. Anderson S, Shires VL, Wilson RA, Mountford AP (1998) In the absence of IL-12, the induction of Th1-mediated protective immunity by the attenuated schistosome vaccine is impaired, revealing an alternative pathway with Th2-type characteristics. *Eur J Immunol* 28: 2827-2838.
38. Bergquist R, Utzinger J, McManus DP (2008) Trick or treat: the role of vaccines in integrated schistosomiasis control. *PLoS Negl Trop Dis* 2: e244.
39. Smythies LE, Betts C, Coulson PS, Dowling MA, Wilson RA (1996) Kinetics and mechanism of effector focus formation in the lungs of mice vaccinated with irradiated cercariae of *Schistosoma mansoni*. *Parasite Immunol* 18: 359-369.
40. Dean DA (1983) *Schistosoma* and related genera: acquired resistance in mice. *Exp Parasitol* 55: 1-104.
41. Wynn TA, Jankovic D, Hieny S, Cheever AW, Sher A (1995) IL-12 enhances vaccine-induced immunity to *Schistosoma mansoni* in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinophilia. *J Immunol* 154: 4701-4709.
42. Mountford AP, Anderson S, Wilson RA (1996) Induction of Th1 cell-mediated protective immunity to *Schistosoma mansoni* by co-administration of larval antigens and IL-12 as an adjuvant. *J Immunol* 156: 4739-4745.
43. Tendler M, Simpson AJ (2008) The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. *Acta Trop* 108: 263-266.
44. Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA (2010) Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with *Schistosoma mansoni* in mice. *Int J Infect Dis* 14: e781-787.
45. Zhang W, Ahmad G, Torben W, Siddiqui AA (2010) Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with *Schistosoma mansoni* in mouse. *Parasite Immunol* 32: 252-258.
46. Zhang W, Ahmad G, Torben W, Noor Z, Le L, et al. (2010) Sm-p80-based DNA vaccine provides baboons with levels of protection against *Schistosoma mansoni* infection comparable to those achieved by the irradiated cercarial vaccine. *J Infect Dis* 201: 1105-1112.
47. El Ridi R, Tallima H (2012) Adjuvant Selection for Vaccination against Murine Schistosomiasis. *Scand J Immunol* 76: 552-558.
48. Grzych JM, Pearce E, Cheever A, Caulada ZA, Caspar P, et al. (1991) Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis *mansoni*. *J Immunol* 146: 1322-1327.
49. Pearce EJ, Caspar P, Grzych JM, Lewis FA, Sher A (1991) Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, *Schistosoma mansoni*. *J Exp Med* 173: 159-166.

50. Amiri P, Locksley RM, Parslow TG, Sadick M, Rector E, et al. (1992) Tumour necrosis factor alpha restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice [see comments]. *Nature* 356: 604-607.
51. Cheever AW, Eltoun IA, Andrade ZA, Cox TM (1993) Biology and pathology of *Schistosoma mansoni* and *Schistosoma japonicum* infections in several strains of nude mice. *Am J Trop Med Hyg* 48: 496-503.
52. Patton EA, Brunet LR, La Flamme AC, Pedras-Vasconcelos J, Kopf M, et al. (2001) Severe schistosomiasis in the absence of interleukin-4 (IL-4) is IL-12 independent. *Infect Immun* 69: 589-592.
53. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN (2000) Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. *J Immunol* 164: 2585-2591.
54. Hoffmann KF, Cheever AW, Wynn TA (2000) IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. *J Immunol* 164: 6406-6416.
55. Jankovic D, Kullberg MC, Noben-Trauth N, Caspar P, Ward JM, et al. (1999) Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile. *J Immunol* 163: 337-342.
56. Stadecker MJ, Asahi H, Finger E, Hernandez HJ, Rutitzky LI, et al. (2004) The immunobiology of Th1 polarization in high-pathology schistosomiasis. *Immunol Rev* 201: 168-179.
57. Mountford AP, Shires VL, Anderson S (1998) Interleukin-12 and protective immunity to schistosomes. *Braz J Med Biol Res* 31: 163-169.
58. Mountford AP, Coulson PS, Pemberton RM, Smythies LE, Wilson RA (1992) The generation of interferon-gamma-producing T lymphocytes in skin-draining lymph nodes, and their recruitment to the lungs, is associated with protective immunity to *Schistosoma mansoni*. *Immunology* 75: 250-256.
59. Mwatha JK, Kimani G, Kamau T, Mbugua GG, Ouma JH, et al. (1998) High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN- gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. *J Immunol* 160: 1992-1999.
60. Abath FGC, Morais CNL, Montenegro CEL, Wynn TA, Montenegro SML (2006) Immunopathogenic mechanisms in schistosomiasis: what can be learnt from human studies? *Trends in Parasitology* 22: 85-91.
61. Hernandez HJ, Edson CM, Harn DA, Ianelli CJ, Stadecker MJ (1998) *Schistosoma mansoni*: genetic restriction and cytokine profile of the CD4 + T helper cell response to dominant epitope peptide of major egg antigen Sm-p40. *Exp Parasitol* 90: 122-130.
62. Hernandez HJ, Trzyna WC, Cordingley JS, Brodeur PH, Stadecker MJ (1997) Differential antigen recognition by T cell populations from strains of mice developing polar forms of granulomatous inflammation in response to eggs of *Schistosoma mansoni*. *Eur J Immunol* 27: 666-670.
63. Wynn TA, Cheever AW, Williams ME, Hieny S, Caspar P, et al. (1998) IL-10 regulates liver pathology in acute murine *Schistosomiasis mansoni* but is not

- required for immune down-modulation of chronic disease. *J Immunol* 160: 4473-4480.
64. He Y-X, Chen L, Ramaswamy K (2002) *Schistosoma mansoni*, *S. haematobium*, and *S. japonicum*: early events associated with penetration and migration of schistosomula through human skin. *Experimental Parasitology* 102: 99-108.
  65. Jenkins SJ, Hewitson JP, Jenkins GR, Mountford AP (2005) Modulation of the host's immune response by schistosome larvae. *Parasite Immunol* 27: 385-393.
  66. Ramaswamy K, Kumar P, He YX (2000) A role for parasite-induced PGE2 in IL-10-mediated host immunoregulation by skin stage schistosomula of *Schistosoma mansoni*. *J Immunol* 165: 4567-4574.
  67. Angeli V, Faveeuw C, Roye O, Fontaine J, Teissier E, et al. (2001) Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. *J Exp Med* 193: 1135-1147.
  68. Herve M, Angeli V, Pinzar E, Wintjens R, Faveeuw C, et al. (2003) Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion. *Eur J Immunol* 33: 2764-2772.
  69. Chen L (2002) Skin-stage *Schistosomula* of *Schistosoma mansoni* Produce an Apoptosis-inducing Factor That Can Cause Apoptosis of T Cells. *Journal of Biological Chemistry* 277: 34329-34335.
  70. Brannstrom K, Sellin ME, Holmfeldt P, Brattsand M, Gullberg M (2009) The *Schistosoma mansoni* protein Sm16/SmSLP/SmSPO-1 assembles into a nine-subunit oligomer with potential To inhibit Toll-like receptor signaling. *Infect Immun* 77: 1144-1154.
  71. Mangold BL, Dean DA (1984) The migration and survival of gamma-irradiated *Schistosoma mansoni* larvae and the duration of host-parasite contact in relation to the induction of resistance in mice. *Parasitology* 88 ( Pt 2): 249-265.
  72. Dean DA, Mangold BL, Georgi JR, Jacobson RH (1984) Comparison of *Schistosoma mansoni* migration patterns in normal and irradiated cercaria-immunized mice by means of autoradiographic analysis. Evidence that worm elimination occurs after the skin phase in immunized mice. *Am J Trop Med Hyg* 33: 89-96.
  73. Pemberton RM, Smythies LE, Mountford AP, Wilson RA (1991) Patterns of cytokine production and proliferation by T lymphocytes differ in mice vaccinated or infected with *Schistosoma mansoni*. *Immunology* 73: 327-333.
  74. Wilson RA, Coulson PS, Betts C, Dowling MA, Smythies LE (1996) Impaired immunity and altered pulmonary responses in mice with a disrupted interferon-gamma receptor gene exposed to the irradiated *Schistosoma mansoni* vaccine. *Immunology* 87: 275-282.
  75. Betts CJ, Wilson RA (1998) Th1 cytokine mRNA expression dominates in the skin-draining lymph nodes of C57BL/6 mice following vaccination with irradiated *Schistosoma mansoni* cercariae, but is down-regulated upon challenge infection. *Immunology* 93: 49-54.
  76. Hogg KG, Kumkate S, Anderson S, Mountford AP (2003) Interleukin-12 p40 secretion by cutaneous CD11c+ and F4/80+ cells is a major feature of the innate immune response in mice that develop Th1-mediated protective immunity to *Schistosoma mansoni*. *Infect Immun* 71: 3563-3571.

77. de Oliveira Fraga LA, Lamb EW, Moreno EC, Chatterjee M, Dvorak J, et al. Rapid induction of IgE responses to a worm cysteine protease during murine pre-patent schistosome infection. *BMC Immunol* 11: 56.
78. de Oliveira Fraga LA, Torrero MN, Tocheva AS, Mitre E, Davies SJ (2010) Induction of type 2 responses by schistosome worms during prepatent infection. *J Infect Dis* 201: 464-472.
79. Leptak CL, McKerrow JH (1997) Schistosome egg granulomas and hepatic expression of TNF-alpha are dependent on immune priming during parasite maturation. *J Immunol* 158: 301-307.
80. Gordon S (2003) Alternative activation of macrophages. *Nat Rev Immunol* 3: 23-35.
81. Raes G, De Baetselier P, Noel W, Beschin A, Brombacher F, et al. (2002) Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. *J Leukoc Biol* 71: 597-602.
82. Stout RD (2010) Editorial: macrophage functional phenotypes: no alternatives in dermal wound healing? *J Leukoc Biol* 87: 19-21.
83. Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, et al. (2004) Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. *Immunity* 20: 623-635.
84. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, et al. (2009) Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. *PLoS Pathog* 5: e1000371.
85. Coker CM (1957) Effect of Cortisone on Natural Immunity to *Schistosoma mansoni* in Mice. *Proc Soc Exp Biol Med* 96: 1-3.
86. Weinmann CJ, Hunter GW (1960) Studies on Schistosomiasis. XIV. Effects of Cortisone upon the *Schistosoma mansoni* Burden in Mice. *Exp Parasitol* 9: 239-242.
87. Doenhoff M, Musallam R, Bain J, McGregor A (1978) Studies on the host-parasite relationship in *Schistosoma mansoni*- infected mice: the immunological dependence of parasite egg excretion. *Immunology* 35: 771-778.
88. Harrison RA, Doenhoff MJ (1983) Retarded development of *Schistosoma mansoni* in immunosuppressed mice. *Parasitology* 86: 429-438.
89. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, et al. (1992) RAG-1-deficient mice have no mature B and T lymphocytes. *Cell* 68: 869-877.
90. Davies SJ, Grogan JL, Blank RR, Lim KC, Locksley RM, et al. (2001) Modulation of Blood Fluke Development in the Liver by Hepatic CD4+ Lymphocytes. *Science* 294: 1358-1361.
91. Lamb E, Crow E, Lim K, Liang Y, Lewis F, et al. (2007) Conservation of CD4+ T cell-dependent developmental mechanisms in the blood fluke pathogens of humans. *International Journal for Parasitology* 37: 405-415.
92. Lamb EW, Walls CD, Pesce JT, Riner DK, Maynard SK, et al. (2010) Blood fluke exploitation of non-cognate CD4+ T cell help to facilitate parasite development. *PLoS Pathog* 6: e1000892.
93. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* 282: 2085-2088.

94. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, et al. (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. *Nature* 424: 743-748.
95. Takeda K, Akira S (2004) TLR signaling pathways. *Semin Immunol* 16: 3-9.
96. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. *Int Immunol* 17: 1-14.
97. Takeda K, Akira S (2007) Toll-like receptors. *Curr Protoc Immunol* Chapter 14: Unit 14 12.
98. van der Kleij D, Latz E, Brouwers JF, Kruize YC, Schmitz M, et al. (2002) A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. *J Biol Chem* 277: 48122-48129.
99. Thomas PG, Carter MR, Atochina O, Da'Dara AA, Piskorska D, et al. (2003) Maturation of dendritic cell 2 phenotype by a helminth glycan uses a Toll-like receptor 4-dependent mechanism. *J Immunol* 171: 5837-5841.
100. Jenkins SJ, Hewitson JP, Ferret-Bernard S, Mountford AP (2005) Schistosome larvae stimulate macrophage cytokine production through TLR4-dependent and -independent pathways. *Int Immunol* 17: 1409-1418.
101. Allen JE, Wynn TA (2011) Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. *PLoS Pathog* 7: e1002003.
102. Meleney HE, Moore DV, Most H, Carney BH (1953) The histopathology of experimental schistosomiasis. I. The hepatic lesions in mice infected with *S. mansoni*, *S. japonicum* and *S. haematobium*. *Am J Trop Med Hyg* 1: 263-285.
103. Page CR, 3rd, Etges FJ (1971) Experimental prepatent schistosomiasis mansoni: host mortality and pathology. *Am J Trop Med Hyg* 20: 894-903.
104. Matzinger P (1994) Tolerance, danger, and the extended family. *Annu Rev Immunol* 12: 991-1045.
105. Kono H, Rock KL (2008) How dying cells alert the immune system to danger. *Nat Rev Immunol* 8: 279-289.
106. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* 440: 237-241.
107. Ogura Y, Sutterwala FS, Flavell RA (2006) The Inflammasome: First Line of the Immune Response to Cell Stress. *Cell* 126: 659-662.
108. Ritter M, Gross O, Kays S, Ruland J, Nimmerjahn F, et al. (2010) *Schistosoma mansoni* triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. *Proc Natl Acad Sci U S A* 107: 20459-20464.
109. Timms AR, Bueding E (1959) Studies of a proteolytic enzyme from *Schistosoma mansoni*. *Br J Pharmacol Chemother* 14: 68-73.
110. Wilson RA (2012) Virulence factors of schistosomes. *Microbes Infect* 14: 1442-1450.

## **Chapter 2**

**Regulation of pro-inflammatory responses during pre-patent schistosome  
infection creates an immune environment permissive for parasite development**

## Abstract

Helminth blood flukes of the genus *Schistosoma* infect over 200 million people. As a result of host-parasite co-evolution, *S. mansoni* evolved to exploit host immune factors as signals to coordinate its own development. Worms fail to develop normally in RAG<sup>-/-</sup> mice, lacking T and B cells, while development is restored by adoptive transfer of CD4<sup>+</sup> T cells, suggesting that CD4<sup>+</sup> T cells play a central role in regulating parasite development. Recent findings suggest the role of CD4<sup>+</sup> T cells in this process is indirect, being limited to provision of non-cognate T cell help for innate responses which, in turn, facilitate parasite development. In support of this hypothesis, we have found that long-term administration of LPS to RAG<sup>-/-</sup> mice, in the absence of CD4<sup>+</sup> T cells, also restores worm development, indicating that innate immune signals are sufficient for parasite development to proceed normally. LPS activates TLR-4 resulting in production of TNF- $\alpha$  and IL-1 $\beta$ . However, chronic administration of LPS down-regulates the pro-inflammatory response leading us to hypothesize that regulation of innate immune responses are necessary for restoration of *S. mansoni* development. In support of this hypothesis we found blocking TNF- $\alpha$  or administering IL-4 resulted in decreased expression of IL-1 $\beta$  in *S. mansoni* infected RAG<sup>-/-</sup> mice, as well as, restored parasite development. Current research efforts are focused on how regulation of IL-1 $\beta$  influences schistosome development. Elucidation of the innate immune signals that control schistosome development could provide leads for the development of new drug targets and vaccine strategies.

## Introduction

As a result of extensive host-parasite co-evolution, helminths exploit resources within their hosts to complete their development and ensure transmission to new hosts. Indeed, most helminths are obligate parasites, requiring the intra-host environment for successful life cycle completion. However, for the most part, the precise host factors that helminths require or utilize, in terms of host cells or molecules, are poorly defined. Previously, CD4<sup>+</sup> T cells were shown to play a fundamental role in schistosome development [1-3], with significant impairment of parasite growth and reproductive activity occurring in the absence of CD4<sup>+</sup> T cells. While the precise mechanism by which CD4<sup>+</sup> T-cells mediate this effect is unclear, the mechanism is indirect, as chronic stimulation of innate immune responses with LPS, a toll-like receptor 4 (TLR4) agonist, during pre-patent infection was able to restore parasite development in the absence of CD4<sup>+</sup> T cells [4]. Thus, all the host factors necessary for schistosome development are present, or at least can be induced, independently of CD4<sup>+</sup> T cells. However, whether the mechanisms by which CD4<sup>+</sup> T cells and chronic LPS stimulation restore schistosome development share any common elements has remained an open question.

Regulation of proinflammatory responses is critical for control of *S. mansoni* infections [5] as well as survival from gram negative sepsis [6]. In the case of schistosomes, and other helminths in general, infection results in the establishment of robust Th2 responses that modulate pro-inflammatory processes [7,8]. In schistosomiasis, Th2 responses against parasite antigens are required for the formation of protective



granulomas around parasite eggs [9,10]. Th2 responses to worm antigens develop even before the onset of egg production [11,12] and there is evidence that this immune priming by the developing worms is necessary to ensure proper Th2 granuloma formation [13]. Th2 responses are also critical for host survival after egg production begins, as lack of IL-4 signaling leads to severe disease and early mortality as a result of excessive pro-inflammatory processes [9,10,14-16]. Thus, in schistosomiasis, Th2 responses serve a dual purpose, to mediate granuloma formation and to regulate inflammation.

Here, we present evidence to suggest that, while fundamentally different, chronic exposure of immunodeficient mice to inflammatory stimuli and CD4<sup>+</sup> T cells in immunocompetent mice ultimately promote parasite development by resulting in a similar outcome, namely the establishment of an immunological milieu where inflammatory processes are regulated. These findings provide insights into the developmental requirements of schistosomes and may identify host dependencies that could be exploited to disrupt schistosome infection.

## Materials and Methods

### Ethics statement:

All animal studies were conducted in accordance with established protocols approved by the USUHS Institutional Animal Care and Use Committee.

### Experimental mice:

RAG-1<sup>-/-</sup> mice on a C57BL/6 background were originally purchased from Jackson laboratory (Bar Harbor, ME) and then bred in-house for experimental use. C57BL/6 mice were purchased from the National cancer institute (NCI, Frederick, MD). RAG-1<sup>-/-</sup> IL-1R<sup>-/-</sup> were generated by crossing C57BL/6 RAG-1<sup>-/-</sup> to C57BL/6 IL-1R<sup>-/-</sup> mice purchased from Jackson laboratory (Bar Harbor, ME). The RAG-1<sup>-/-</sup> IL-1R<sup>-/-</sup> genotype was confirmed via PCR. All mice used in experiments were age matched.

### Parasite parameters:

Mice were infected percutaneously via tail exposure to water containing 160 *S. mansoni* cercariae (Puerto Rican strain) shed from infected *Biomphalaria glabrata* snails. At 6 weeks post infection (p.i.) mice were sacrificed. Worms were perfused from the portal system and immediately fixed in 4% neutral buffered formaldehyde. Male and female worms were counted and photographed at 20x magnification using a Nikon D80

10.0 megapixel digital camera attached to a Zeiss trinocular dissecting microscope.

Worm growth was assessed by measuring the length of male worms from digital micrographs Image J software (<http://rsb.info.nih.gov/ij>), as described previously[4]. Only male worms were measured as female growth is dependent upon receiving developmental cues from pairing with maturing males [17]. Sexual maturation of the parasites was assessed by calculating egg production per worm pair from liver egg burdens, as described previously[4]. Briefly, liver tissue was homogenized and digested in 0.7% trypsin phosphate buffered saline (PBS) solution and the released eggs were counted under a dissecting microscope.

Measuring areas of liver inflammation and coagulative necrosis:

C57BL/6 wild type and RAG-1<sup>-/-</sup> mice were infected with cercariae as described above. At 4 weeks p.i., mice were sacrificed and their livers removed and immediately fixed in 35 ml of 4% neutral buffered formaldehyde. Liver sections were cut and stained with hematoxylin and eosin stain (H&E stain, Histoserv INC., Germantown, MD). Slides were digitally scanned using the Hamamatsu Nanozoomer 2.0RS (Hamamatsu City, Japan). Tissue sections were analyzed using the Nanozoomer digital pathology (NDP) software. At low magnification, random areas of liver tissue measuring 20 mm<sup>2</sup> in total were selected. The selected sections were then scanned at 5X magnification and areas of inflammation were measured. For each liver, sections were obtained at 3 different levels and measurements were taken for at least 3 different tissue sections. The percentage area of inflammation was determined by summing up the area occupied by inflammatory

infiltrate and dividing it by the total area examined. The percentage area occupied by coagulative necrosis was determined by the same method.

Acetaminophen (AAP) and D-(+)-galactosamine hydrochloride (GalN) treatment:

RAG-1<sup>-/-</sup> mice were infected with cercariae as described above. Mice received weekly intraperitoneal (i.p.) injections of AAP (Sigma-Aldrich, St Louis, MO) at a dose of 5 mg/mouse dissolved in 100 µl 30% DMSO for the first 3 weeks. Mice then received AAP at a dose of 10 mg/mouse dissolved in 30% DMSO for the remaining 3 weeks. Control mice received weekly i.p. injections of 30% DMSO. D-GalN (MP Biomedicals, Solon, OH) -treated mice received biweekly i.p. injections at a dose of 10mg/mouse for 6 weeks, using PBS without calcium and magnesium as a vehicle. Control mice received biweekly i.p. injections of PBS (Mediatech, Manassas, VA) alone. At 6 weeks p.i. mice were sacrificed, H&E staining of livers was performed to confirm liver inflammation in treated mice, and parasite parameters were determined as described above.

Monosodium urate (MSU), Alum, LPS, and Poly-IC treatment:

RAG-1<sup>-/-</sup> mice were infected with cercariae as described above. Mice received biweekly i.p. injections of MSU (Invivogen, San Diego, CA) at a dose of 500 µg/mouse, Inject Alum (Thermo Scientific, Rockford, IL) at a dose of 1 mg/mouse, ultrapure LPS, *E.coli* 0111:B4 (Invivogen) at a dose of 20 µg/mouse, or Poly-IC 20 µg or 40 µg /mouse. Control mice received biweekly i.p. injections of PBS without calcium and magnesium.

At 6 weeks p.i. mice were sacrificed and parasite parameters were determined as described above.

#### Anti-TNF- $\alpha$ treatment:

RAG-1<sup>-/-</sup> mice were infected with cercariae as previously described. Mice received weekly i.p. injections of Adalimumab (Abbott, Chicago, IL) at a dose of 100  $\mu$ g/mouse, using PBS without calcium and magnesium as a vehicle. Control mice received weekly i.p. injections of PBS alone. At 6 weeks p.i., mice were sacrificed and parasite parameters were determined as described above.

#### IL-4 complex treatment

RAG-1<sup>-/-</sup> mice were infected with cercariae as described above. Mice received weekly i.p. injections of 5  $\mu$ g IL-4 (Peprotech, Rocky Hill, New Jersey) complexed to 25  $\mu$ g anti-IL-4 antibody 11B11 (BioXCell, West New Lebanon, New Hampshire) (Jenkins, 2011). Control mice received weekly i.p. injections of the isotype control antibody HRPN (BioXCell). At 6 weeks p.i. mice were sacrificed, H&E staining of livers was performed to confirm liver inflammation in treated mice, and parasite parameters were determined as described above.

#### RNA isolation, purification, and Real time PCR

RNA was isolated from the spleens and/or livers of wild type or RAG-1<sup>-/-</sup> mice. After removal, tissues were immediately placed in 1 ml RNA-BEE (Tel-Test, Friendswood, Texas), homogenized, snap-frozen in liquid nitrogen and stored at -80°C until isolation of total RNA, following manufacturer's instructions. RNA was further purified following the RNeasy mini protocol for RNA cleanup (Qiagen, Valencia, California). Purified RNA was quantified using a ND-1000 spectrophotometer (Nanodrop, Wilmington, DE). 2 ug of RNA was used for cDNA preparation using a high capacity RNA to cDNA kit (Invitrogen, Grand Island, New York) following manufacturer's instructions. Real time PCR was performed with a MJ Research Chromo4 PTC-200 thermocycler unit (Bio-Rad, Hercules, CA) using Taqman gene expression assays and TaqMan gene expression master mix (Invitrogen) following manufacturer's instructions. Assays for the following mRNAs were performed: *rsp29*, *GAPDH*, *IL-1 $\beta$* , *TNF- $\alpha$* , *CCL2*, *Relm- $\alpha$* , and *YM1*. Expression of genes of interest was normalized to the expression of *GAPDH* or *rsp29* and fold changes in expression were calculated following the  $2^{-\Delta\Delta CT}$  method [18].

### Statistical analysis

All statistical analyses were performed using GraphPad Prism Inc. version 4.0 software (San Diego, California). Significant differences between two groups were determined using a student's unpaired T-test with Welch's correction or a Mann-Whitney test. Significant differences between 3 or more groups were determined using a Kruskal-Wallis test followed by a Dunn's multiple comparison test. *P* values of less than 0.05

were considered significant. 3-5 mice were used per experimental group and each experiment was repeated at least twice.

## Results

### *Pre-patent S. mansoni infection fails to induce liver inflammation and necrosis in immunodeficient mice*

Although chronic lipopolysaccharide stimulation, administered twice weekly during the first six weeks of infection, can restore schistosome development in RAG<sup>-/-</sup> mice, this stimulus is not present at high concentrations in mouse plasma. We therefore sought to identify other inflammatory processes occurring during the pre-patent stage of schistosome infection in normal mice, but not in RAG<sup>-/-</sup> mice, as these might be candidates for a physiological stimulus for parasite development. Before the deposition of eggs, worm development in the portal vasculature is associated with both liver inflammation and hepatocellular necrosis of an unknown etiology [19,20]. To determine whether this pathology also occurs in RAG<sup>-/-</sup> mice, we compared liver tissue sections from 4 week-infected RAG<sup>-/-</sup> and wild type mice. As previously reported [19,20], wild type mice exhibited areas of coagulative necrosis and infiltration with inflammatory cells (Figure 1A). Inflammatory infiltrates, consisting of lymphocytes, eosinophils and mononuclear cells, were located in periportal areas and in the parenchyma, and also surrounded necrotic areas (Figure 1A). In contrast, areas of coagulative necrosis were not seen in the 4 week-infected RAG<sup>-/-</sup> mice (Figure 1B), with the exception of two animals where small foci of necrosis were detected (data points included in Figure 1C). Furthermore, we observed very little liver inflammation in 4 week-infected RAG<sup>-/-</sup> mice (Figure 1B), which, when present, was restricted to areas around or near vessel walls



(figure 1B). The mean percentage area occupied by necrotic liver tissue was 1.6 % for wild type animals, while RAG<sup>-/-</sup> mice exhibited almost none (Figure 1C). Likewise, the mean percentage area occupied by inflammatory infiltrates was 8.7 % in wild type mice, while RAG<sup>-/-</sup> mice exhibited almost none (Figure 1D). These data show that failure of parasite development in RAG<sup>-/-</sup> mice correlates with a lack of liver necrosis and inflammation. Furthermore, while the etiology of the liver necrosis in wild type mice is unknown, these data suggest that death of hepatocytes during pre-patent schistosome infection requires an intact adaptive immune system.

*Endogenous danger-associated molecular patterns restore S. mansoni development in immunodeficient mice.*

In view of the fact that a failure of parasite development in RAG<sup>-/-</sup> mice correlates with a lack of liver necrosis and inflammation, we hypothesized that induction of liver necrosis and inflammation would restore parasite development in these animals. To test this hypothesis, we administered hepatotoxins (either acetaminophen or D-galactosamine) to RAG<sup>-/-</sup> mice throughout pre-patent infection, at doses sufficient to result in hepatocellular death and inflammation [21-24], in an attempt to simulate the cell death observed in wild type mice. While chronic hepatotoxin treatment did not recapitulate the coagulative necrosis seen in wild type mice, both treatments induced histological evidence of widespread hepatocellular damage (data not shown). Furthermore, both treatments partially restored parasite growth when compared to control

RAG<sup>-/-</sup> animals that received vehicle alone (figure 2A and 2B), while parasite egg production was unaffected (data not shown).

Cellular injury results in the release of uric acid into the extracellular environment [25-28] that crystallizes to form monosodium urate (MSU) [29,30], an endogenous DAMP that activates the NALP3 inflammasome [31]. Since chronic hepatotoxin treatment partially restored parasite development in RAG<sup>-/-</sup> mice, we hypothesized that DAMP-mediated inflammatory processes would also restore parasite development in these animals. To test this hypothesis, we administered MSU to infected RAG<sup>-/-</sup> mice throughout the first six weeks of infection and compared worm development to that in control RAG<sup>-/-</sup> mice that received vehicle alone. Treatment with MSU resulted in robust restoration of parasite growth (Figure 2C) and egg production (Figure 2D) in RAG<sup>-/-</sup> mice suggesting that, like LPS, chronic DAMP-mediated inflammation can also stimulate parasite development. In further support of a role for inflammasome-mediated inflammation in stimulating parasite development, we also found that treatment with alum, an exogenous NALP3 inflammasome agonist [32,33], also resulted in robust restoration of parasite growth (Figure 2E) and egg production (Figure 2F) in RAG<sup>-/-</sup> mice. Taken together, these data suggest that, like the exogenous danger signal LPS, endogenous danger signals that stimulate inflammation via inflammasomes can also stimulate schistosome development.

*Parasite development correlates with regulation of IL-1 $\beta$  transcription*

By serving as a molecular platform for caspase 1 activation, inflammasomes drive IL-1 $\beta$ -mediated inflammation by catalyzing the conversion of inactive pro-IL-1 $\beta$  to the bioactive form. As two different inflammasome agonists restored parasite development in RAG<sup>-/-</sup> mice, we hypothesized that IL-1 $\beta$ -mediated inflammation may be implicated in controlling parasite development. To address this issue, we first examined IL-1 $\beta$  mRNA levels during pre-patent infection of wild type mice. Unexpectedly, we found that steady-state splenic mRNA levels of IL-1 $\beta$  in wild type mice at 3 and 4 weeks p.i. were downregulated compared to the baseline levels found in non-infected control mice (Figure 3A). In contrast, IL-1 $\beta$  mRNA levels remained unchanged in the spleens of 4 week-infected RAG<sup>-/-</sup> mice when compared to non-infected controls (Figure 3B). Thus, normal parasite development correlated with downregulation of steady-state IL-1 $\beta$  transcription. To test whether a failure to downregulate IL-1 $\beta$  signaling in RAG<sup>-/-</sup> mice is the cause of impaired schistosome development in these animals, we infected RAG<sup>-/-</sup> IL-1R<sup>-/-</sup> knockout mice, predicting that, if this were the case, ablation of IL-1 signaling would restore parasite development in a RAG-deficient context. However, worms recovered from RAG<sup>-/-</sup> IL-1R<sup>-/-</sup> mice 6 weeks p.i. did not differ significantly from those obtained from RAG<sup>-/-</sup> mice, being small in size (Figure 3C) and reproductively inactive (Figure 3D). Therefore, parasite development correlates with regulation of IL-1 $\beta$  transcription, but IL-1R signaling is not directly responsible for inhibiting parasite development in RAG<sup>-/-</sup> mice.

*Chronic innate immune stimulation with LPS or MSU results in downregulation of proinflammatory signals*

As our examination of IL-1 $\beta$  transcription in wild type and RAG<sup>-/-</sup> mice revealed that normal schistosome development correlated with downregulation of IL-1 $\beta$  transcription, we next examined the effect of the LPS and MSU treatment regimens on IL-1 $\beta$  transcription in RAG<sup>-/-</sup> mice, as both treatments restore parasite development in these animals. Treatment with LPS (Figure 4A) or MSU (Figure 4B) throughout the first six weeks of infection resulted in downregulation of splenic IL-1 $\beta$  mRNA levels in infected RAG<sup>-/-</sup> mice by week six post infection, similar to the downregulation seen in infected wild type mice (Figure 3A). Thus, while downregulation of IL-1 $\beta$  transcription is mediated by the adaptive immune system in wild type mice, chronic administration of LPS or MSU to RAG<sup>-/-</sup> mice can also result in IL-1 $\beta$  downregulation, in the absence of an adaptive immune system. Furthermore, chronic LPS and MSU treatments resulted in downregulation of other proinflammatory signals, as evidenced by reduced splenic mRNA levels for TNF (Figure 4C and 4D) and CCL2 (Figure 4E and 4F), a chemokine important for inflammatory macrophage recruitment [34-36]. Finally, we found that transcriptional downregulation of proinflammatory genes to levels lower than those in control animals required chronic exposure to MSU (Supplementary Figure 1 A-C), as transcription of proinflammatory genes peaked rapidly following a single injection of MSU (data not shown) and then returned to the levels observed in non-treated mice by 18 hours post injection (Supplemental Figure 1 D-F).

*Parasites fail to develop when proinflammatory gene transcription is sustained*

Our analysis of wild type, RAG<sup>-/-</sup> and MSU- and LPS-treated RAG<sup>-/-</sup> mice showed that normal parasite development correlates with the overall downregulation of proinflammatory gene transcription. However, we considered the possibility that elevated proinflammatory gene transcription early in the course of LPS or MSU treatment, before regulation was induced, could be the factor stimulating parasite development rather than the ultimately downregulated state. To explore this possibility we sought to identify comparable treatments where chronic administration of an inflammatory stimulus did not result in downregulated proinflammatory gene expression. To this end, we found that administration of poly I:C [37], a TLR3 ligand, to RAG<sup>-/-</sup> mice throughout the first six weeks of infection, resulted in upregulation of splenic mRNA for IL-1 $\beta$ , TNF, and CCL2 (Figure 5 A-C), rather than their downregulation. Consistent with a role for proinflammatory gene downregulation in permitting schistosome development, chronic administration of poly I:C also failed to restore parasite development in RAG<sup>-/-</sup> mice, as worms recovered from treated animals did not differ significantly in size (figure 5D-E) or egg output (data not shown) from vehicle-treated controls at either of the two doses tested.

#### *TNF blockade restores parasite development in immunodeficient mice*

As restoration of parasite development in RAG<sup>-/-</sup> mice correlated with downregulation of proinflammatory gene transcription (in LPS- and MSU-treated RAG<sup>-/-</sup> mice) and was unaltered when proinflammatory gene transcription was sustained (in poly I:C-treated RAG<sup>-/-</sup> mice), we hypothesized that it was the downregulation of

proinflammatory genes that permits parasite development to proceed. To test this hypothesis, we attempted to suppress proinflammatory gene activity in RAG<sup>-/-</sup> mice by blocking TNF signaling with a neutralizing antibody, which has been shown to decrease IL-1 $\beta$  production in models of sepsis [38-40] and arthritis [41]. Administration of the anti-TNF antibody did not cause acute increases in proinflammatory gene expression (data not shown), and its administration throughout pre-patent infection led to the downregulation of IL-1 $\beta$ , TNF- $\alpha$ , and CCL2 transcription in the spleens of RAG<sup>-/-</sup> mice by four weeks post infection (Figure 6A-C), similar to that observed in wild type mice and with chronic LPS or MSU treatment in RAG<sup>-/-</sup> mice. Furthermore, anti-TNF treatment resulted in significant increases in parasite size (Figure 6D) and reproductive activity (Figure 6E) when compared to control RAG<sup>-/-</sup> mice. Thus, these data supported our hypothesis that schistosome development requires the downregulation of proinflammatory gene transcription during pre-patent infection.

#### *Administration of IL-4 complex restores parasite development in immunodeficient mice*

In *S. mansoni*-infected wild type mice, downregulation of IL-1 $\beta$  transcription occurs via an adaptive immune mechanism, as there is a failure of IL-1 $\beta$  mRNA downregulation when the adaptive immune system is ablated (Figure 3). In previous studies, we showed that, prior to the onset of egg production, pre-patent schistosome infection results in the rapid establishment of a T helper 2 response [11,12], where CD4<sup>+</sup> T cells produce significant quantities of IL-4 in response to worm antigens [11]. As IL-4 is a type 2 cytokine that regulates proinflammatory signals, including IL-1 $\beta$  [42-44], we

hypothesized that IL-4 may represent the adaptive mechanism by which IL-1 $\beta$  is regulated in wild type mice. To test whether IL-4 was sufficient to regulate proinflammatory gene transcription in RAG<sup>-/-</sup> mice, we administered IL-4 complex (IL-4c) to infected RAG<sup>-/-</sup> mice during pre-patent infection and examined proinflammatory gene transcription in the spleen at week six post infection. Administration of IL-4c resulted in down-regulation of IL-1 $\beta$  and TNF transcription in the spleens of treated RAG<sup>-/-</sup> mice (Figure 7A and 7B), similar to that observed in wild type mice and RAG<sup>-/-</sup> mice treated with LPS, MSU or anti-TNF. Transcription of CCL2 was also reduced by IL-4c treatment, although the difference between treated and control animals narrowly avoided attaining statistical significance (Figure 7C). The transcription of RELM- $\alpha$  and YM1, both markers of alternative macrophage activation [45], was dramatically up-regulated in the spleens (data not shown) and the livers of IL-4c-treated animals (Figure 7D and 7E), suggesting that IL-4c treatment induced an innate type 2 response and the accumulation of alternatively activated macrophages in livers of RAG<sup>-/-</sup> mice. Indeed, administration of IL-4c also restored the accumulation of mononuclear cells in the livers (Figure 7F) of infected RAG<sup>-/-</sup> mice and induced giant cell formation (Figure 7G), a previously reported hallmark of alternatively activated macrophage responses [46]. Finally, administration of IL-4c resulted in the restoration of parasite growth (Figure 7H) and reproductive activity (Figure 7I). Our data demonstrate that IL-4, a type 2 cytokine produced as part of the adaptive immune response to pre-patent schistosome infection, is sufficient to regulate proinflammatory signals and restore schistosome development and may represent the mechanism by which CD4<sup>+</sup> T cells permit normal parasite development in wild type mice.





## Discussion

Numerous lines of evidence indicate that type 2 responses are beneficial in schistosome infection, not because these responses mediate immunity against schistosomes but because they limit potentially damaging proinflammatory responses. For example, in mice deficient in IL-4, IL-4 and IL-10, IL-4 and IL-13 or IL-4 receptor, decreased host survival is observed during acute schistosome infection due to excessive proinflammatory cytokine expression and increased liver and intestinal pathology [9,10,15,47]. Likewise, in schistosomiasis patients, severe disease is correlated with decreased production of type 2 cytokines and elevated levels of IFN- $\gamma$ , TNF and NO [48]. However, there is also evidence that type 2 responses ultimately benefit schistosomes, and that this benefit extends beyond the obvious relationship between extended host survival and the increased likelihood of transmission to snail intermediate hosts. For example, it has long been recognized that egress of schistosome eggs across the bowel wall is immune-dependent [49]. Subsequent macrophage-specific ablation of IL-4R expression showed that IL-4/IL-13-responsive macrophages are specifically required for egg passage into the intestinal lumen. These observations suggest that host-parasite co-evolution has not only selected for immune responses that prolong host survival, but also for parasites that are able to take advantage of the resulting immunological milieu. The data we present here support the hypothesis that control of proinflammatory signals may also be intimately linked to parasite development before the onset of egg production.

Our finding that chronic stimulation with LPS could restore schistosome development in RAG<sup>-/-</sup> mice presented a paradox, as there is no obvious parallel between the inflammatory response to LPS and the response induced by pre-patent schistosome infection in wild type mice. However inflammation, albeit in response to necrotic hepatocytes, is a feature of pre-patent schistosome infection in immune-competent, but not RAG<sup>-/-</sup> mice, suggesting there is a link between inflammation and normal parasite development. In support of this hypothesis, we show here that restoration of DAMP-mediated inflammation in RAG<sup>-/-</sup> mice also restored parasite development. While endogenous DAMPs stimulate inflammation by pathways distinct from exogenous PAMPs such as LPS, our finding that both can restore parasite development suggests it is the inflammation itself rather than the inciting cause that modulates parasite development. The contribution of necrosis-induced inflammation to promoting parasite development in wild type mice is an interesting and unresolved question. One way to address this question may be to inhibit necrosis in wild type mice and examine for effects on parasite development. Identification of the mechanism leading to hepatocellular necrosis in wild type mice may make this approach possible. The absence of necrosis in RAG<sup>-/-</sup> mice suggests that adaptive responses are involved in necrosis induction. Alternatively, the lack of necrosis in these animals may be a result of diminished parasite growth, rather than a cause. However, we have not observed hepatocellular necrosis in RAG<sup>-/-</sup> mice where parasite development is restored by LPS treatment (data not shown), suggesting that developing parasites do not directly cause liver necrosis.

Our observation that steady state transcription of the pro-inflammatory cytokine IL-1 $\beta$  is down-regulated in infected wild type mice, but not in RAG<sup>-/-</sup> animals, further

suggested a role for inflammatory processes in schistosome development, but in an inhibitory capacity. However, the permissiveness of wild type mice for parasite development is not specifically due to downregulation of IL-1 signaling, as ablation of IL-1R activity in a RAG<sup>-/-</sup> context did not restore parasite development. This result led us to hypothesize that parasite development may require the more general regulation of proinflammatory processes that is mediated by type 2 responses, such as those induced by pre-patent schistosome infection. If this hypothesis were correct, we predicted that chronic LPS or MSU administration restored parasite development in RAG<sup>-/-</sup> mice because they also result in regulation of inflammatory signaling. The induction of LPS tolerance in response to repeated LPS exposure is a well-recognized negative feedback mechanism, thought to be mediated by a variety of mechanisms including regulation of downstream protein kinases, resulting in downregulation of inflammatory cytokine transcription [6]. However, we show here that chronic MSU exposure also results in downregulation of proinflammatory signals. While MSU signals via pathways distinct from LPS, the existence of negative feedback mechanisms that limit the damage that may be caused by persistent MSU signaling is not unexpected. Evidence for the induction of anti-inflammatory mechanisms by endogenous DAMPs exists. First, toxicological injury to the liver by AAP first results in an early pro-inflammatory response that is directed by classically activated M1 macrophages, but this initial response is followed by suppression of the initial pro-inflammatory response and promotion of wound healing by immunoregulatory, alternatively activated (M2) macrophages [50,51]. Second, both alum and uric acid have been shown to promote Th2 immunity and suppression of pro-inflammatory processes through NALP3 independent mechanisms [52,53]. Similarly,

LPS tolerance is associated with induction of immunoregulatory M2 macrophages [54]. Based on our findings, we hypothesized that LPS and MSU restored parasite development in RAG<sup>-/-</sup> mice by virtue of their ability to induce regulation of pro-inflammatory signals when administered chronically, thus mimicking the regulation associated with type 2 responses that normally occur during pre-patent infection of wild type mice.

To further test whether inflammation per se, or the regulation that results from the inflammation was required for parasite development, we sought to identify inflammatory stimuli that did not lead to regulation. We found that the TLR3 ligand poly I:C, even when administered repeatedly on the same regimen as LPS or MSU, failed to reduce baseline levels of inflammatory gene transcription, resulting instead in overall elevated levels of transcription, even 18 hours post administration. Unlike other TLR ligands like LPS, which stimulate MyD88-dependent signaling, poly I:C responses are propagated via distinct TRIF-mediated pathways that appear not to be subject to the same negative feedback regulation. Chronic poly I:C administration therefore afforded us the opportunity to examine schistosome development in the context of persistent inflammation without the associated regulation. Consistent with a role for regulation in parasite development rather than inflammation, chronic administration of poly I:C, at two different doses, failed to enhance parasite development.

Because poly I:C signaling is mediated via a distinct receptor and adapter molecule, we cannot exclude the possibility that some essential component of the response induced by MSU or LPS is absent from the response to poly I:C. However, we reasoned that if regulation of inflammation was the critical element in permitting parasite

development, then direct regulation of inflammation in the absence of exogenous inflammatory stimuli would also be able to restore schistosome development. The success of anti-TNF neutralization therapy in controlling inflammatory disorders is due to the ability of this intervention in broadly controlling inflammation, mediated by TNF and associated signals, including IL-1 $\beta$ . In the absence of any additional inflammatory stimuli, administration of anti-TNF antibodies to infected RAG<sup>-/-</sup> mice recapitulated the regulation of inflammatory gene transcription observed after chronic LPS or MSU administration and also restored schistosome development, lending further support to the necessity of regulation for normal parasite development.

In an immunocompetent host, pre-patent schistosome infection induces a Th2 response, characterized by production of IL-4 by CD4<sup>+</sup> T cells in response to schistosome antigens. In addition to driving Th2 effector mechanisms such as antibody isotype class switch recombination in B cells and M2 macrophage development, IL-4 also regulates pro-inflammatory signals and is therefore a likely principle regulator of pro-inflammatory processes during pre-patent schistosome infection. We therefore hypothesized that regulation mediated by IL-4 may be the principle contribution of the adaptive response in wild type mice to permitting parasite development. Consistent with this role, IL-4 administration to RAG<sup>-/-</sup> mice was sufficient to restore regulation of IL-1 $\beta$  and TNF transcription and induce type 2 responses, and also restored parasite development. Thus, a single type 2 cytokine was sufficient to significantly augment schistosome growth and egg production. Despite this finding, IL-4 is unlikely to be the only host factor to promote schistosome development, as parasite development proceeds normally when IL-4 signaling is blocked in otherwise immunologically intact mice, whether by anti-IL-4

antibody or through genetic disruption. We therefore conclude there is likely considerable redundancy in the requirement of schistosomes for regulation, as illustrated by the diversity of mechanisms by which parasite development can be restored in RAG<sup>-/-</sup> mice (chronic administration of LPS or MSU, or administration to anti-TNF antibody or IL-4). These findings also suggest that the host elements required for schistosome development may be common components to the responses induced by each of these mediators. For example, development of alternatively activated M2 macrophages rather than classically activated M1 macrophages is promoted in each of these immunological situations [54-59]. Thus M2 macrophages are one possible host factor that schistosomes co-opt to complete development. There is already evidence for schistosome dependence on M2 macrophages later in infection, as these cells are critical to the egress of schistosome eggs from the body of the host. As M2 macrophages are a specific hallmark of the host response to schistosomes and other helminths, the hypothesis that schistosomes have evolved to specifically exploit this aspect of the host response is an attractive one.

Why regulation of pro-inflammatory signals would influence schistosome development remains to be determined. Allen and Wynn recently suggested that Th2 immunity evolved in order to supply a fast response and to repair the tissue damage generated by helminthes[60] , highlighting that the need for regulation of innate immune responses is not limited to schistosome infections but is a feature of many immune responses directed towards tissue-penetrating helminths. For example, M2 macrophages and the generation of Th2 responses are critical for limiting lung tissue damage after experimental *N. brasiliensis* infection [61], by controlling initial IL-17-driven inflammatory responses and promoting resolution of tissue damage [62]. AAMs have

also been shown to limit brain tissue pathology in a murine model for neurocysticercosis [63]. Both STAT6<sup>-/-</sup> mice [64] and TLR2<sup>-/-</sup> [63] mice had decreased numbers of AAMs found in brains containing *Mesocestoides corti* cysts compared to infected wild type controls resulting in increased parasite burden and disease severity. The generation of Th2 responses has been shown to occur early in *S. mansoni* infection [11,12] and is critical for host survival after egg production begins [9,10,14-16]. Macrophages particularly alternatively activated macrophages are of critical importance in the regulation of excessive egg-induced inflammation and the lack AAMs during acute infection is lethal, as shown by the macrophage-specific ablation of IL-4R $\alpha$  expression [47]. How type 2 responses contribute to schistosome development remains unclear. As mediators of tissue repair and remodeling, one possibility is that M2 cells mediate critical niche remodeling in portal venules where the rapidly growing schistosomes reside, akin to the lymphatic vascular remodeling induced by filarial nematodes. Alternatively, the presence of M2 macrophages may alter the availability of host-derived nutrients or other molecules that the developing parasites require. Macrophage activation status is associated with profound changes in cell metabolism that could influence the concentrations of host factors in the immediate vicinity of larval schistosomes. Alternatively molecules associated with immunoregulation and type 2 responses may be recognized by schistosomes and utilized as signals of an environment that is appropriate for parasite development. A somewhat similar relationship was recently proposed to influence the development of *Litomosoides (L.) sigmodontis*, a filarial nematode, which speeds up its larval development and produces greater numbers of microfilaria in response to IL-5 and eosinophils. It was suggested that these parasites utilize IL-5 as a

predictor for future survival and altered life expectancy [65]. Studies to examine these and other possibilities in the context of schistosome infection are currently underway.

Here we presented evidence that regulation of pro-inflammatory processes is a contributor to determining the developmental fate of schistosomes in their definitive mammalian host. It remains to be determined how schistosomes might recognize a regulated immune environment and how this environment influences parasite development. However, these findings suggest that inflammation and its regulation are key components of a host environment permissive to schistosome infection and suggest that modulation of inflammatory processes may be a useful target for disrupting schistosome infection and could lead to new insights for improved treatments or vaccine development.



## References

1. Davies SJ, Grogan JL, Blank RB, Lim KC, Locksley RM, et al. (2001) Modulation of Blood Fluke Development in the Liver by Hepatic CD4<sup>+</sup> Lymphocytes. *Science* 294: 1358-1361.
2. Lamb EW, Crow ET, Lim KC, Liang YS, Lewis FA, et al. (2007) Conservation of CD4<sup>+</sup> T cell-dependent developmental mechanisms in the blood fluke pathogens of humans. *Int J Parasitol* 37: 405-415.
3. Harrison RA, Doenhoff MJ (1983) Retarded development of *Schistosoma mansoni* in immunosuppressed mice. *Parasitology* 86: 429-438.
4. Lamb EW, Walls CD, Pesce JT, Riner DK, Maynard SK, et al. (2010) Blood fluke exploitation of non-cognate CD4<sup>+</sup> T cell help to facilitate parasite development. *PLoS Pathog* 6: e1000892.
5. Stadecker MJ, Asahi H, Finger E, Hernandez HJ, Rutitzky LI, et al. (2004) The immunobiology of Th1 polarization in high-pathology schistosomiasis. *Immunol Rev* 201: 168-179.
6. Biswas SK, Lopez-Collazo E (2009) Endotoxin tolerance: new mechanisms, molecules and clinical significance. *Trends Immunol* 30: 475-487.
7. Pearce EJ, MacDonald AS (2002) The immunobiology of schistosomiasis. *Nat Rev Immunol* 2: 499-511.
8. Pearce EJ, C MK, Sun J, J JT, McKee AS, et al. (2004) Th2 response polarization during infection with the helminth parasite *Schistosoma mansoni*. *Immunol Rev* 201: 117-126.
9. Brunet LR, Finkelman FD, Cheever AW, Kopf MA, Pearce EJ (1997) IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis. *J Immunol* 159: 777-785.
10. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN (2000) Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. *J Immunol* 164: 2585-2591.
11. de Oliveira Fraga LA, Torrero MN, Tocheva AS, Mitre E, Davies SJ (2010) Induction of type 2 responses by schistosome worms during prepatent infection. *J Infect Dis* 201: 464-472.
12. de Oliveira Fraga LA, Lamb EW, Moreno EC, Chatterjee M, Dvorak J, et al. Rapid induction of IgE responses to a worm cysteine protease during murine pre-patent schistosome infection. *BMC Immunol* 11: 56.
13. Leptak CL, McKerrow JH (1997) Schistosome egg granulomas and hepatic expression of TNF-alpha are dependent on immune priming during parasite maturation. *J Immunol* 158: 301-307.
14. Patton EA, Brunet LR, La Flamme AC, Pedras-Vasconcelos J, Kopf M, et al. (2001) Severe schistosomiasis in the absence of interleukin-4 (IL-4) is IL-12 independent. *Infect Immun* 69: 589-592.
15. Hoffmann KF, Cheever AW, Wynn TA (2000) IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms

- of lethal immunopathology in murine schistosomiasis. *J Immunol* 164: 6406-6416.
16. Jankovic D, Kullberg MC, Noben-Trauth N, Caspar P, Ward JM, et al. (1999) Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile. *J Immunol* 163: 337-342.
  17. Hernandez DC, Lim KC, McKerrow JH, Davies SJ (2004) *Schistosoma mansoni*: sex-specific modulation of parasite growth by host immune signals. *Exp Parasitol* 106: 59-61.
  18. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402-408.
  19. Meleney HE, Moore DV, Most H, Carney BH (1953) The histopathology of experimental schistosomiasis. I. The hepatic lesions in mice infected with *S. mansoni*, *S. japonicum* and *S. haematobium*. *Am J Trop Med Hyg* 1: 263-285.
  20. Page CR, 3rd, Etges FJ (1971) Experimental prepatent schistosomiasis mansoni: host mortality and pathology. *Am J Trop Med Hyg* 20: 894-903.
  21. Chen GY, Tang J, Zheng P, Liu Y (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. *Science* 323: 1722-1725.
  22. Chung H, Kim HJ, Jang KS, Kim M, Yang J, et al. (2006) Comprehensive analysis of differential gene expression profiles on D-galactosamine-induced acute mouse liver injury and regeneration. *Toxicology* 227: 136-144.
  23. McCuskey RS, Bethea NW, Wong J, McCuskey MK, Abril ER, et al. (2005) Ethanol binging exacerbates sinusoidal endothelial and parenchymal injury elicited by acetaminophen. *J Hepatol* 42: 371-377.
  24. Keppler D, Lesch R, Reutter W, Decker K (1968) Experimental hepatitis induced by D-galactosamine. *Exp Mol Pathol* 9: 279-290.
  25. Kono H, Chen CJ, Ontiveros F, Rock KL (2010) Uric acid promotes an acute inflammatory response to sterile cell death in mice. *J Clin Invest* 120: 1939-1949.
  26. Shi Y (2010) Caught red-handed: uric acid is an agent of inflammation. *J Clin Invest* 120: 1809-1811.
  27. Malhi H, Guicciardi ME, Gores GJ (2010) Hepatocyte death: a clear and present danger. *Physiol Rev* 90: 1165-1194.
  28. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, et al. (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. *Nat Med* 13: 851-856.
  29. Ghaemi-Oskouie F, Shi Y (2011) The role of uric acid as an endogenous danger signal in immunity and inflammation. *Curr Rheumatol Rep* 13: 160-166.
  30. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. *Nature* 425: 516-521.
  31. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* 440: 237-241.
  32. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. *Nature* 453: 1122-1126.

33. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, et al. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. *Nat Immunol* 9: 847-856.
34. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV, Jr., et al. (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. *J Clin Invest* 100: 2552-2561.
35. Aldridge JR, Jr., Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, et al. (2009) TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. *Proc Natl Acad Sci U S A* 106: 5306-5311.
36. Szymczak WA, Deepe GS, Jr. (2009) The CCL7-CCL2-CCR2 axis regulates IL-4 production in lungs and fungal immunity. *J Immunol* 183: 1964-1974.
37. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature* 413: 732-738.
38. Fong Y, Moldawer LL, Marano M, Wei H, Barber A, et al. (1989) Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. *Am J Physiol* 256: R659-665.
39. Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. *Eur Cytokine Netw* 6: 225-230.
40. Redl H, Schlag G, Paul E, Bahrami S, Buurman WA, et al. (1996) Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia. *Am J Physiol* 271: R1193-1198.
41. Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, et al. (2001) IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. *J Immunol* 166: 1214-1222.
42. Cao Y, Brombacher F, Tunyogi-Csapo M, Glant TT, Finnegan A (2007) Interleukin-4 regulates proteoglycan-induced arthritis by specifically suppressing the innate immune response. *Arthritis Rheum* 56: 861-870.
43. Martinez FO, Helming L, Gordon S (2009) Alternative activation of macrophages: an immunologic functional perspective. *Annu Rev Immunol* 27: 451-483.
44. Macedo FY, Mourao LT, Freitas HC, Lima RC, Jr., Wong DV, et al. (2012) Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis. *Inflammation* 35: 297-307.
45. Raes G, De Baetselier P, Noel W, Beschin A, Brombacher F, et al. (2002) Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. *J Leukoc Biol* 71: 597-602.
46. McNally AK, Anderson JM (1995) Interleukin-4 induces foreign body giant cells from human monocytes/macrophages. Differential lymphokine regulation of macrophage fusion leads to morphological variants of multinucleated giant cells. *Am J Pathol* 147: 1487-1499.
47. Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, et al. (2004) Alternative macrophage activation is essential for survival during schistosomiasis

- and downmodulates T helper 1 responses and immunopathology. *Immunity* 20: 623-635.
48. Dunne DW, Pearce EJ (1999) Immunology of hepatosplenic schistosomiasis mansonii: a human perspective. *Microbes Infect* 1: 553-560.
  49. Doenhoff M, Musallam R, Bain J, McGregor A (1978) Studies on the host-parasite relationship in *Schistosoma mansonii*- infected mice: the immunological dependence of parasite egg excretion. *Immunology* 35: 771-778.
  50. Laskin DL (2009) Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. *Chem Res Toxicol* 22: 1376-1385.
  51. Holt MP, Cheng L, Ju C (2008) Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. *J Leukoc Biol* 84: 1410-1421.
  52. Kuroda E, Ishii Ken J, Uematsu S, Ohata K, Coban C, et al. (2011) Silica Crystals and Aluminum Salts Regulate the Production of Prostaglandin in Macrophages via NALP3 Inflammasome-Independent Mechanisms. *Immunity* 34: 514-526.
  53. Kool M, Willart Monique AM, van Nimwegen M, Bergen I, Pouliot P, et al. (2011) An Unexpected Role for Uric Acid as an Inducer of T Helper 2 Cell Immunity to Inhaled Antigens and Inflammatory Mediator of Allergic Asthma. *Immunity* 34: 527-540.
  54. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, et al. (2009) Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor B. *Proceedings of the National Academy of Sciences* 106: 14978-14983.
  55. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, et al. (2001) Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. *Arthritis Rheum* 44: 186-195.
  56. Smeets TJ, Kraan MC, van Loon ME, Tak PP (2003) Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. *Arthritis Rheum* 48: 2155-2162.
  57. De Rycke L, Baeten D, Foell D, Kruithof E, Veys EM, et al. (2005) Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. *J Pathol* 206: 17-27.
  58. Martin WJ, Shaw O, Liu X, Steiger S, Harper JL (2011) MSU crystal-recruited non-inflammatory monocytes differentiate into M1-like pro-inflammatory macrophages in a peritoneal murine model of gout. *Arthritis Rheum*.
  59. Yagnik DR, Evans BJ, Florey O, Mason JC, Landis RC, et al. (2004) Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. *Arthritis Rheum* 50: 2273-2280.
  60. Allen JE, Wynn TA (2011) Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. *PLoS Pathog* 7: e1002003.
  61. Reece JJ, Siracusa MC, Scott AL (2006) Innate immune responses to lung-stage helminth infection induce alternatively activated alveolar macrophages. *Infect Immun* 74: 4970-4981.

62. Chen F, Liu Z, Wu W, Rozo C, Bowdridge S, et al. (2012) An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. *Nat Med* 18: 260-266.
63. Gundra UM, Mishra BB, Wong K, Teale JM (2011) Increased disease severity of parasite-infected TLR2<sup>-/-</sup> mice is correlated with decreased central nervous system inflammation and reduced numbers of cells with alternatively activated macrophage phenotypes in a murine model of neurocysticercosis. *Infect Immun* 79: 2586-2596.
64. Mishra BB, Gundra UM, Teale JM (2011) STAT6<sup>(-)/(-)</sup> mice exhibit decreased cells with alternatively activated macrophage phenotypes and enhanced disease severity in murine neurocysticercosis. *J Neuroimmunol* 232: 26-34.
65. Babayan SA, Read AF, Lawrence RA, Bain O, Allen JE (2010) Filarial parasites develop faster and reproduce earlier in response to host immune effectors that determine filarial life expectancy. *PLoS Biol* 8: e1000525.

**Figure 1. Early *S. mansoni* infection fails to induce liver inflammation and coagulative necrosis in RAG<sup>-/-</sup> mice.**


Wild type (C57BL/6) and RAG<sup>-/-</sup> mice were infected with *S. mansoni* cercariae via percutaneous tail exposure. Digital images of liver sections (4 weeks p.i.) were obtained using Nanozoomer microscope and areas of inflammation and coagulative necrosis were measured using nanozoom digital software. (A) H&E stained liver section from a wild type mice exhibiting periportal infiltration of inflammatory cells, as well as, infiltration of inflammatory cells into the parenchyma (arrows). Example of coagulative necrosis also found in 4 wk infected wild type mice (\*). (B) H&E stained liver section from RAG<sup>-/-</sup> exhibiting only small areas of periportal infiltration of inflammatory cells (arrows). (C) Total percentage of coagulative necrosis was calculated per animal (n=8) and mean values are represented by horizontal bars. (D) Total percentage of inflammatory infiltrate was calculated per animal (n=8) and mean values are represented by horizontal bars. P values were determined using the Mann Whitney test.



**Figure 2. Inducing hepatocyte death and inflammasome activation facilitates *S. mansoni* development in RAG<sup>-/-</sup> mice.**


Parasite development was restored after inducing chronic liver inflammation or chronic administration of NALP3 inflammasome agonists as determined by (A) Length of male worms recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment twice a week with 10 mg D-(+)-galactosamine hydrochloride (GalN). (B) Length of male worms recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment once a week with 5 mg acetaminophen (AAP) for the first 3 weeks then 10 mg AAP for the last 3 weeks of infection. (C and E) Length of male worms and (D and F) egg production by schistosome pairs recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment twice a week with 500 µg monosodium urate (MSU) or 1 mg alum. Mean values are represented by horizontal bars. Groups of 4 to 5 mice were used for each experimental condition. P values for worm lengths determined using student's T-test with Welch's correction. P values for egg production determined using the Mann Whitney test. Data shown for the MSU experiment is pooled from 2 independent experiments.






**Figure 3. *S. mansoni* development occurs in the context of down-regulated IL-1 $\beta$  expression.**

(A) Splenic IL-1 $\beta$  levels are down-regulated in 3 and 4 week schistosome infected C57BL/6 mice as compared to uninfected controls (B) Splenic IL-1 $\beta$  levels are unchanged in 4 week schistosome infected RAG<sup>-/-</sup> mice as compared to uninfected controls. Groups of 3 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined for 3 and 4 week infected wild type mice mRNA expression levels using an ANOVA with a Tukey post-test and for 4 week infected RAG<sup>-/-</sup> mice using the Mann Whitney test. (C) Length of male worms and (D) egg production by schistosome pairs recovered from RAG<sup>-/-</sup> or RAG<sup>-/-</sup> IL-1R<sup>-/-</sup> mice at 6 weeks p.i.. Groups of 5 mice were used for each experimental condition. P values for worm lengths were determined using student's T-test with Welch's correction. P values for egg production were determined using the Mann Whitney test.








**Figure 4. Chronic TLR-4 or NALP3 inflammasome activation results in regulation of pro-inflammatory cytokine gene expression.**

Splenic IL-1 $\beta$  (A and B) TNF- $\alpha$  (C and D) and CCL2 (E and F) mRNA levels are down-regulated in 6 week schistosome infected RAG<sup>-/-</sup> mice treated twice a week with either 20  $\mu$ g LPS or 500 ug MSU as compared to 6 week schistosome infected PBS treated RAG<sup>-/-</sup> mice. Groups of 5 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined using the Mann Whitney test.



**Figure 5. Chronic TLR-3 signaling results in up-regulation of pro-inflammatory gene expression and fails to restore *S. mansoni* development in immunodeficient mice.**






Splenic (A) IL-1 $\beta$  (B) TNF- $\alpha$  and (C) CCL2 mRNA levels are up-regulated in 6 week schistosome infected RAG<sup>-/-</sup> mice treated twice a week with 20  $\mu$ g poly I:C. Groups of 5 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined using the Mann Whitney test. (C) Length of male worms recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment twice a week with 20  $\mu$ g poly I:C. (D) Length of male worms recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment twice a week with 40  $\mu$ g poly I:C. Groups of 5 mice were used for each experimental condition. P values for worm lengths were determined using student's T-test with Welch's correction.



**Figure 6. Inducing regulation of pro-inflammatory cytokines via blockade of TNF restores *S. mansoni* development in RAG<sup>-/-</sup> mice.**

Splenic (A) IL-1 $\beta$  (B) TNF- $\alpha$  and (C) CCL2 mRNA levels are down-regulated in 6 week schistosome infected RAG<sup>-/-</sup> mice treated once a week with 100  $\mu$ g anti-TNF as compared to 6 week schistosome infected PBS treated RAG<sup>-/-</sup> mice. Groups of 5 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined using the Mann Whitney test. Length of male worms (D) and (E) egg production by schistosome pairs recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment once a week with 100  $\mu$ g anti-TNF as compared to vehicle treated controls. Groups of 5 mice were used for each experimental condition. P values for worm lengths were determined using student's T-test with Welch's correction. P values for egg production were determined using the Mann Whitney test.







**Figure 7. IL-4 promotes a Th2-like environment that facilitates *S. mansoni* development in RAG<sup>-/-</sup> mice.**

Schistosome infected RAG<sup>-/-</sup> mice were treated weekly with 5 µg IL-4 complexed to 25 µg anti-IL-4 antibody 11B11 (IL-4c) for 6 weeks in order to promote a Th2-like environment. H&E images from a treated animal 6 weeks p.i. (A) highlighting macrophages (small arrows) in the inflammatory infiltrate surrounding worm pigment (large arrows) and (B) giant cell formation (arrows). ) Splenic (C) IL-1β and (D) TNF-α mRNA levels are down-regulated in IL-4c treated RAG<sup>-/-</sup> mice as compared to PBS treated RAG<sup>-/-</sup> mice. Splenic CCL2 (E) mRNA levels did not differ significantly between the experimental and control groups. P values were determined using the Mann Whitney test. Liver (F) RELM-α and (G) YM1 mRNA levels are upregulated in IL-4c treated RAG<sup>-/-</sup> mice as compared to PBS treated RAG<sup>-/-</sup> mice. Mean values are represented by horizontal bars. Groups of 3 to 5 mice were used for each experimental condition. (H) Length of male worms and (I) egg production by schistosome pairs recovered from RAG<sup>-/-</sup> mice treated with IL-4c or PBS. Mean values are represented by horizontal bars. Groups of 3 to 5 mice were used for each group. P values for worm lengths were determined using student's T-test with Welch's correction. P values for egg production were determined using the Mann Whitney test.


A




B




C




D




E




F




G



H









I



**Supplemental Figure 1. Long term MSU administration results in the regulation of pro-inflammatory responses.**

Liver (A) IL-1 $\alpha$  (B) IL-1 $\beta$  and (C) CCL2 mRNA levels are down-regulated in 6 week schistosome infected RAG<sup>-/-</sup> mice treated twice weekly with 500  $\mu$ g MSU as compared to 6 week schistosome infected PBS treated RAG<sup>-/-</sup> mice. (D) IL-1 $\alpha$  (E) IL-1 $\beta$  and (F) CCL2 liver mRNA levels in RAG<sup>-/-</sup> mice return to baseline 18 hours after receiving a 500  $\mu$ g dose of MSU as compared to PBS treated controls. Mean values are represented by horizontal bars. Groups of 5 mice were used for each experimental condition. P values were determined using the Mann Whitney test.



### **Chapter 3**

**Restoration of *Schistosoma mansoni* development in immunodeficient mice by  
chronic TLR stimulation is dependent on MyD88 signaling**

## Abstract

Blood flukes of the genus *Schistosoma* infect 200 million people. As a result of host parasite co-evolution, *S. mansoni* has evolved to exploit host immune factors as signals to coordinate its own development within the host. Worms fail to develop normally in RAG<sup>-/-</sup> mice that lack all T and B cells, while development is restored when CD4<sup>+</sup> T cells are transferred into RAG<sup>-/-</sup> mice, suggesting that CD4<sup>+</sup> T cells play a central role in regulating parasite development. The role of CD4<sup>+</sup> T cells in this process is indirect, and is limited to the provision of non-cognate T cell help for innate responses which, in turn, facilitate parasite development. Indeed, T-cells can be bypassed completely in this process. The direct activation of innate immune system via chronic TLR stimulation via PAMPs in the absence of T-cells also restores worm development, indicating that innate immune signals are sufficient for parasite development to proceed normally. However, restoration of parasite development via chronic TLR stimulation requires MyD88 dependent signaling resulting in the regulation of pro-inflammatory cytokine transcription that creates an immune environment permissive for parasite development to proceed in immunodeficient mice.

## Introduction

Schistosomiasis, a disease caused by parasitic blood flukes, has plagued humans from antiquity [1] up to the present time, with an estimated 239 million people infected [2] and another approximately 700 million people at risk or acquiring the infection [3]. The vast majority of schistosome infections occur in sub-saharan Africa, with *S. mansoni* contributing significantly to this disease burden [4,5]. Schistosomiasis is responsible for an estimated annual loss of 70 million disability adjusted life years (DALYs), putting it ahead of malaria as parasitic cause for disease burden [6]. Once infected, an individual can harbor schistosomes for years, despite robust immune responses directed towards the parasite and its eggs.

As a result of extensive host-parasite co-evolution, *S. mansoni* and other schistosomes have likely evolved to exploit host immune factors to complete their development within the host, as parasite development is greatly attenuated in immunodeficient hosts. Host CD4<sup>+</sup> T cells appear central to parasite development, as CD4<sup>+</sup> T cells are sufficient to restore parasite development in immunodeficient hosts [7,8]. However, the role that T cells play in this process is indirect and is mediated through provision of T cell help for innate immune components, as the requirement for CD4<sup>+</sup> T cells can be circumvented completely by the direct stimulation of innate immune responses via lipopolysaccharide- (LPS-) mediated activation of toll-like receptor (TLR)-4 [9].



While there are numerous examples of bacterial, viral, fungal, and protozoan pathogen associated molecular patterns (PAMPs) [10-12] worm antigens have not been shown to robustly activate innate immune responses via TLR signaling. Furthermore, while LPS has been shown to reach significant concentrations in the blood of schistosomiasis patients, this is probably the result of intestinal mucosal damage induced by parasite eggs and is unlikely to occur before the onset of oviposition, when the parasites are developing. These two observations brought into question the physiological relevance of TLR4 activation in schistosome development.

We therefore sought to establish whether *S.mansoni* development in RAG<sup>-/-</sup> mice could be restored through chronic stimulation with other bacterial, viral and fungal PAMPs that signal through other TLRs. As TLRs can be broadly categorized based on subcellular localization as either plasma membrane-bound or endosomal, we also tested whether receptor location impacted any potential effects on parasite development. Finally, as TLR signaling is propagated by two distinct pathways, distinguished by involvement of two different adaptor proteins, MyD88 and TRIF, we tested whether there was evidence for preferential involvement of either pathway in stimulating parasite development.

## Materials and Methods

### Ethics statement:

All animal studies were conducted in accordance with established protocols approved by the USUHS Institutional Animal Care and Use Committee.

### Experimental mice:

RAG-1<sup>-/-</sup> mice on a C57BL/6 background were originally purchased from Jackson laboratory (Bar Harbor, ME) and then bred in-house for experimental use. All mice used in experiments were age matched.

### Parasite parameters:

Mice were infected percutaneously via tail exposure to water containing 160 *S. mansoni* cercariae (Puerto Rican strain) shed from infected *Biomphalaria glabrata* snails. At 6 weeks post infection (p.i.) mice were sacrificed. Worms were perfused from the portal system and immediately fixed in 4% neutral buffered formaldehyde. Male and female worms were counted and photographed at 20x magnification using a Nikon D80 10.0 megapixel digital camera attached to a Zeiss trinocular dissecting microscope. Worm growth was assessed by measuring the length of male worms from digital micrographs Image J software (<http://rsb.info.nih.gov/ij>), as described previously[9]. Only

male worms were measured as female growth is dependent upon receiving developmental cues from pairing with maturing males [13]. Sexual maturation of the parasites was assessed by calculating egg production per worm pair from liver egg burdens, as described previously [9]. Briefly, liver tissue was homogenized and digested in 0.7% trypsin phosphate buffered saline (PBS) solution and the released eggs were counted under a dissecting microscope.

#### TLR stimulation:

RAG-1<sup>-/-</sup> mice were infected with cercariae as described above. Mice received biweekly i.p. 20 µg/mouse injections of one of the following Invivogen TLR ligands: Pam3CSK4 or zymosan (TLR2), poly I:C (TLR3), ultrapure LPS *E.coli* 0111:B4 or MPLA (TLR4), Guardiquimod (TLR7), CpG (TLR9). Control mice received biweekly i.p. injections of PBS without calcium and magnesium. At 6 weeks p.i. mice were sacrificed and parasite parameters were determined as described above.

#### RNA isolation, purification, and Real time PCR

RNA was isolated from the spleens and/or livers of RAG-1<sup>-/-</sup> mice. After removal, tissues were immediately placed in 1 ml RNA-BEE (Tel-Test, Friendswood, Texas), homogenized, snap-frozen in liquid nitrogen and stored at -80°C until isolation of total RNA, following manufacturer's instructions. RNA was further purified following the RNeasy mini protocol for RNA cleanup (Qiagen, Valencia, California). Purified

RNA was quantified using a ND-1000 spectrophotometer (Nanodrop, Wilmington, DE). 2 ug of RNA was used for cDNA preparation using a high capacity RNA to cDNA kit (Invitrogen, Grand Island, New York) following manufacturer's instructions. Real time PCR was performed with a MJ Research Chromo4 PTC-200 thermocycler unit (Bio-Rad, Hercules, CA) using Taqman gene expression assays and TaqMan gene expression master mix (Invitrogen) following manufacturer's instructions. Assays for the following mRNAs were performed: *rsp29*, *GAPDH*, *IL-1 $\beta$* , *TNF- $\alpha$* , *CCL2*, *IFN- $\gamma$* , *IL-6*, *IL-10*, and *NOS2*. Expression of genes of interest was normalized to the expression of *GAPDH* or *rsp29* and fold changes in expression were calculated following the  $2^{-\Delta\Delta CT}$  method [14].

#### Statistical analysis

All statistical analyses were performed using GraphPad Prism Inc. version 4.0 software (San Diego, California). Significant differences for worm lengths between two groups were determined using a student's unpaired T-test with Welch's correction. Significant differences for worm lengths between 3 or more groups were determined using a Kruskal-Wallis test followed by a Dunn's multiple comparisons test. The Mann-Whitney test was utilized to determine significant differences for both eggs/worm pairs as well as splenic or liver fold changes between two groups. *P* values of less than 0.05 were considered significant. 3-5 mice were used per experimental group and each experiment was repeated at least twice.

## Results

### *TLR1/2 stimulation by PAM3CSK4 restores parasite development in immunodeficient mice*

As innate immune activation via LPS and TLR4 signaling has been shown to restore parasite development in RAG<sup>-/-</sup> mice, we tested whether other TLR ligands that shared similar signaling pathways to TLR4 could also restore parasite development in these animals. TLR1/2 and TLR2/6, like TLR4, utilize the adaptor proteins MYD88 and TIRAP/MAL for signaling [10]. We found that administration of Pam3CSK4, a TLR1/2 agonist [15], during prepatent infection resulted in partial restoration of parasite development, as evidenced by increased parasite size (Figure 8A), but egg production, while trending upward, did not differ significantly from the vehicle control group (Figure 1B). On the other hand, administration of zymosan, a yeast TLR2/6 agonist [16], during prepatent infection failed to restore parasite size (Figure 8A) or result in parasite egg production (Figure 8B). Previously, we have shown that restoration of parasite development by LPS coincides with the downregulation of splenic IL-1 $\beta$ , TNF, and CCL2 gene transcription (Chapter 2 Figure 4A-D). As chronic administration of PAM3CSK4 restored parasite size, we hypothesized that this treatment would result in a similar pattern of transcriptional changes. Instead, we found that at 6 weeks post infection, IL-1 $\beta$ , TNF- $\alpha$ , and CCL2 splenic mRNA levels were unchanged in PAM3CSK4-treated animals compared to vehicle controls (Figure 8C-E). However, both IFN- $\gamma$  and IL-6 (Figure 8F-G) mRNA levels were downregulated in the spleens of

PAM3CSK4-treated animals. In contrast, we found that splenic IL-10 mRNA levels were significantly upregulated in PAM3CSK4-treated mice, being 5- to 40-fold higher compared to controls (data points included in Figure 8H). In zymosan-treated animals, there were no significant changes in inflammatory cytokine or IL-10 mRNA (data not shown). These data support our previous conclusion that schistosome development occurs in the context of regulated pro-inflammatory responses and suggests that IL-10 plays a role in regulating inflammation induced by chronic PAM3CSK4 administration.

*Restoration of parasite development in immunodeficient mice is specifically associated with MyD88-dependent regulation and not TLR location*

TLR4 signaling is unique in that it utilizes both the ubiquitous MyD88 adaptor protein and TRIF, a second adaptor protein that is shared only with TLR3 [17]. TLR3 signaling is unique in that it signals solely through the adaptor TRIF [18]. Previously we showed that chronic administration of poly I:C, a mimic of viral double-stranded RNA and a TLR3 agonist [19], failed to restore parasite development in  $RAG^{-/-}$  mice (Chapter 2 Figure 5D-E)). We therefore hypothesized that parasite development is specifically linked to chronic MyD88-dependent stimulation and does not occur in response to TRIF stimulation. To test this hypothesis, we tested whether TRIF-specific signaling via TLR4 would restore parasite development in immunodeficient mice. We found that when we chronically treated infected  $RAG^{-/-}$  mice with monophosphoryl lipid A (MPLA), a TRIF-selective TLR-4 agonist [20], during pre-patent infection, parasite development was not restored. Worms recovered from treated animals did not differ significantly in size

(Figure 9A) or in egg output (data not shown) when compared to vehicle controls. These data suggest that TRIF-mediated signaling alone is not conducive to parasite development and that restoration of parasite development via LPS stimulation of TLR-4 occurs specifically via MyD88 signaling. An alternative explanation we considered for why poly I:C failed to restore parasite development was that, unlike TLR4 and TLR1/2, which are expressed on the plasma membrane, TLR3 is located intracellularly on endosomal membranes. To determine whether TLR location played a role in schistosome development, we tested whether ligands for TLR-7 and TLR-9, which are both endosomal TLRs, could restore parasite development in  $RAG^{-/-}$  mice. We found that chronic administration of CpG, a TLR-9-activating synthetic oligodeoxynucleotide sequence containing unmethylated CG dinucleotides [21,22] partially restored parasite growth compared to t controls that received vehicle alone (figure 9B), while egg production by the worms was unchanged (data not shown). Chronic administration of gardiquimod, a TLR-7-activating imidazoquinoline compound [23], also restored parasite growth (Figure 9C), while egg production trended upwards but narrowly avoided attaining statistical significance (Figure 9D). These findings suggested that TLR location is unimportant with regard to stimulating schistosome development and that the failure of TLR3 signaling to influence parasite development is not due to its endosomal location. Furthermore, these findings suggest that parasite development can be restored by MyD88-dependent TLR stimulation and that the failure of poly I:C (and MPLA) to restore parasite development is due to their utilization of TRIF-dependent signaling.

We further examined the inflammatory cytokine profile resulting from chronic gardiquimod treatment as TLR7, like TLR3, is important for recognition of viral PAMPs,

and we had previously shown that chronic administration of poly I:C resulted in a sustained pro-inflammatory response rather than down-regulation. We found that chronic stimulation with gardiquimod resulted in the downregulation of both TNF and NOS2 (Figure 9E-F) splenic mRNA levels, While splenic mRNA levels for IL-1 $\beta$ , CCL2, IFN- $\gamma$ , IL-6 and IL-10 did not differ from controls (Figure 9G-K). Thus, chronic TLR7 stimulation induced a transcriptional profile distinct from that of chronic TLR3 stimulation, with evidence of down-regulation of inflammatory signals rather than up-regulation. These data suggest that failure of parasites to develop after chronic poly I:C stimulation is linked to the sustained up-regulation of pro-inflammatory cytokine transcription that is unique to poly I:C and TLR3 signaling.

#### *Transcriptional changes associated with restoration or failure of parasite development*

In light of the inflammatory cytokine mRNA transcription patterns generated in response to chronic TLR1/2 and TLR7 stimulation, we tested whether any of these transcriptional changes were also associated with treatments we had previously identified as either restorative (LPS) or not restorative (poly I:C) of parasite development. Like PAM3CSK4 (TLR1/2) stimulation, chronic LPS stimulation also resulted in the downregulation of splenic IL-6 and IFN- $\gamma$  (Figure 10A-B) and, like gardiquimod (TLR7), the downregulation of NOS2 (Figure 10C). However, unlike PAM3CSK4, chronic LPS stimulation did not result in the upregulation of IL-10 and instead, IL-10 transcription levels did not differ from the control group (Figure 10D). This finding suggests that IL-10 may play a more significant role in the regulation induced by chronic



administration of PAM3CSK4 than by chronic administration of LPS. In contrast, chronic poly I:C stimulation resulted in upregulation of IFN- $\gamma$  and NOS2 (Figure 10F,-10G), showing again that chronic poly I:C administration results in sustained inflammation. Interestingly, chronic poly I:C administration also induced upregulation of IL-10 transcription (Figure 10H), in conjunction with inflammatory genes, indicating that this regulatory cytokine is induced by poly I:C, despite the overall pattern of sustained inflammation associated with poly I:C administration.

*Lack of correlation between presence of parasite eggs and liver cytokine transcription*

Our data demonstrate that restoration of parasite development in RAG<sup>-/-</sup> mice occurs in the context of systemic downregulation of pro-inflammatory responses, as evidenced by the reduced transcription of inflammatory genes in the spleen that correlates with restored parasite development. However, during *S. mansoni* development from 1-2 weeks post infection until adulthood occurs in portal venules of the liver, suggesting the liver may be a more relevant site of inflammation and inflammatory regulation early in infection. Indeed, in wild type mice, obvious histological changes of inflammation can be observed during pre-patent infection, in association with areas of hepatocellular necrosis. However analysis of gene expression in the liver is complicated by the fact that, in situations where parasite development is restored, parasite eggs will also begin to accumulate in the liver after week 5 of infection, possibly influencing transcription patterns further. To gain insights into how liver gene expression correlates with parasite development and egg deposition, we examined liver transcription of TNF and IL-10 following treatments that enhance parasite development either with (LPS) or without

(gardiquimod, PAM3CSK4) inducing significant parasite egg accumulation, and compared them with poly I:C treatment, which does not restore parasite development. We found that in animals where treatment fully restored parasite development (LPS), hepatic TNF and IL-10 transcription was modestly elevated relative to control animals (Figure 11A, 11B). However, TNF and IL-10 transcript levels in livers of PAM3CSK4- and gardiquimod-treated animals, where significant egg accumulation did not occur, were either unaffected by treatment (gardiquimod, Figure 11C, 11D) or were strongly up-regulated (PAM3CSK4, Figures 11E, 11F). In the case of the latter, PAM3CSK4 treatment induced an almost 10-fold increase in TNF transcription (Figure 11E), which was accompanied by increase in IL-10 transcription of over 20-fold (Figure 11F). Thus there was no discernible pattern of expression that correlated with the accumulation of parasite eggs.

In comparison, poly I:C treatment also induced an almost 10-fold increase in TNF mRNA in the liver (Figure 11H), but while IL-10 transcription was also significantly increased by poly I:C (Figure 11I), this increase was more modest, on the order of a two-fold increase relative to controls. These findings were in contrast to those obtained with PAM3CSK4. While both stimuli induced robust TNF transcription, only PAM3CSK4 also induced IL-10 at levels that exhibited a strong positive correlation with the induction of TNF (Figure 11G,  $R^2 = 0.9$ ,  $P < 0.05$ ). Poly I:C induced both TNF and IL-10, but the induction of the latter did not correlate with the former (Figure 11J). Thus poly I:C, which does not restore parasite development, again induced an immunological milieu where induction of inflammatory signals was not accompanied by regulation. Taken together this data suggests regulation of pro-inflammatory responses occur in the spleen

rather than the liver. It also once again highlights poly I:C's remarkable ability to maintain sustained inflammation in both the spleen and the liver.

## Discussion

Innate immune responses to acute PAMP/TLR stimulation have been extensively studied and described in the literature [10,11,24,25]. The phenomenon of endotoxin tolerance, where administration of small doses of LPS induces a state of tolerance to subsequent lethal high dose exposure, has also been well characterized [26,27]. However, to our knowledge there are no reports in the literature describing and comparing innate immune responses induced by chronic exposure to various TLR ligands. Here we show that chronic TLR stimulation results in profoundly different immune states, depending upon the PAMP/TLR combination used, and that these different immunological milieus have different effects on the development of *S. mansoni* in immunodeficient mice. Administration of the various TLR ligands to RAG<sup>-/-</sup> mice resulted in three different outcomes. The first, observed after chronic administration of LPS, Pam3CSK4 or guardiquimod, resulted in the regulation of pro-inflammatory cytokine mRNA transcription and was associated with parasite development. Second, chronic administration of the ligands MPLA and zymosan resulted in little change in cytokine mRNA levels when compared to controls and did not restore parasite development. Finally, chronic administration of Poly:Ic resulted in up-regulated pro-inflammatory cytokine mRNA levels, but also did not restore parasite development in RAG<sup>-/-</sup> mice. These results suggest that schistosome development requires the initiation of inflammation and the subsequent induction of regulatory mechanisms to control that inflammation, two criteria that are only met in these experiments when infected animals are administered, LPS, PAM3CSK4 or gardiquimod.

Unlike ligands for TLR-2, TLR-4, and TLR-9 [28-31], we found that repeated administration of Poly:Ic did not induce tolerance to further administration of this stimulus. Instead, chronic administration of Poly-Ic resulted in robust and sustained pro-inflammatory responses (Figure 10E-G and Figure 11H and 11I) and appears to be unique to among the TLR ligands we have examined. Unlike MyD88-dependent ligands, which promote tolerance to one another, TRIF dependent signaling fails to induce tolerance to MyD88-dependent PAMPs and pre-treatment with Poly-Ic, followed by treatment with a MyD88-dependent ligand, resulted in synergistic pro-inflammatory responses [32].

The specific PAMP administered also had an impact on the immune state generated after chronic TLR stimulation. Both zymosan and PAM3CSK4 are TLR-2 ligands, but chronic administration of these ligands results in quite different results. Acute administration of zymosan has been shown to induce IL-10 production, but little to no IL-6 or IL-12(p70), and has been characterized as inducing immunological tolerance [33]. In contrast, acute PAM3CSK4 administration results in robust production of not only IL-10, but also IL-6 and IL-12(p70) [34], as well as TNF [35]. Chronic administration of PAM3CSK4 resulted in the regulation of these pro-inflammatory responses and restored *S. mansoni* development, whereas chronic administration of zymosan had no significant effects on splenic pro-inflammatory cytokine or IL-10 mRNA levels and did not restore parasite development. While the PAM3CSK4 results demonstrate that TLR2 signaling can restore parasite development, we speculate that zymosan failed in this regard because of its failure to induce significant inflammation or regulation after chronic administration.

An alternative explanation for the failure of zymosan and MPLA to create a permissive environment for *S. mansoni* development involves the dosage utilized. Our dosage of 20 µg twice a week is similar to the dosage used to acutely induce immunological tolerance [33], whereas higher doses involving milligrams have been used to induce autoimmune arthritis [36]. Likewise, MPLA has been reported to have only 0.1% of the inflammatory toxicity as LPS, the parent molecule from which it is derived [20,37,38], so while in our hands, 20 µg of LPS was an adequate dose to stimulate inflammation and subsequent regulation, the same dose for MPLA may not have been sufficient for this to occur. However, it is questionable that increasing the dosage of MPLA would result in significantly higher production of pro-inflammatory cytokines. Unlike TRIF dependent poly I:C/TLR3 stimulation, which results in the production of type 1 interferons [39] and pro-inflammatory cytokines such as TNF and IL-6 [32] TRIF-dependent MPLA signaling through TLR4 only resulted in production of IFN-β [20].

The manipulation of innate immune responses by chronic TLR signaling has provided insights into the types of innate responses that support parasite development and those that do not. From these studies, we conclude that regulation of pro-inflammatory responses by chronic TLR agonist administration favors parasite development. We previously showed that administration of IL-4, the hallmark cytokine of Th2 responses, also restores parasite development in RAG<sup>-/-</sup> mice. From that finding and the results presented here, we propose that immunoregulation supportive of parasite growth can occur via different mechanisms. In our experimental RAG<sup>-/-</sup> system, chronic administration of an appropriate TLR agonist can result in regulation of pro-inflammatory signals that promotes parasite growth. However, in immunologically intact

hosts, we propose that Th2 responses provide the regulation of pro-inflammatory signals that is necessary for schistosome development to proceed. A clearer understanding of immune factors that favor parasite development may be relevant to the development of vaccines that prevent schistosome infection [40-42]. To date the most protective vaccine in animal models is the irradiated cercarial vaccine [40,43,44] that induces partial immunity mediated by Th1 responses [45-47]. In contrast, alum, a vaccine adjuvant known to promote Th2-biased responses [48,49], abrogated the protection induced by a DNA vaccine based on a 23 k-Da *S. mansoni* integral membrane protein, a vaccine that, when used alone, induced up to 44% protection to challenge infection [50]. These observations suggest that Th1, rather than Th2 responses may be more successful in mediating protection against schistosome infection. However, there are data to suggest that Th2 responses also participate in mediating protection after vaccination [51,52], as the responses to secondary challenge with normal cercariae after irradiated cercarial vaccination are Th2 and IL-4 mediated [53]. Our data suggest that regulation of pro-inflammatory responses, by Th2 responses or by TLR/Myd88-mediated tolerance, appear to favor parasite development, indicating that maintenance of pro-inflammatory responses to schistosomes may be more effective in disrupting infection.

The data we present here provide insights into how schistosome infection may be influenced by responses induced by TLR agonists, some of which have been proposed to be useful as vaccine adjuvants [54-58]. It remains to be elucidated how schistosomes recognize a regulated immune environment and how that environment is beneficial to the parasite. However, our data suggest that augmentation of inflammatory processes could

be useful for disruption of schistosome infections and to inducing protection from schistosome mediated pathology.





## References

1. Kloos H, David, R. (2002) The Paleoepidemiology of Schistosomiasis in Ancient Egypt. *Research in Human Ecology* 9: 14-25.
2. King CH, Olbrych SK, Soon M, Singer ME, Carter J, et al. (2011) Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. *PLoS Negl Trop Dis* 5: e1321.
3. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis* 6: 411-425.
4. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, et al. (2003) Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop* 86: 125-139.
5. Hotez PJ, Kamath A (2009) Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. *PLoS Negl Trop Dis* 3: e412.
6. King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *The Lancet* 365: 1561-1569.
7. Davies SJ, Grogan JL, Blank RB, Lim KC, Locksley RM, et al. (2001) Modulation of Blood Fluke Development in the Liver by Hepatic CD4+ Lymphocytes. *Science* 294: 1358-1361.
8. Lamb EW, Crow ET, Lim KC, Liang YS, Lewis FA, et al. (2007) Conservation of CD4+ T cell-dependent developmental mechanisms in the blood fluke pathogens of humans. *Int J Parasitol* 37: 405-415.
9. Lamb EW, Walls CD, Pesce JT, Riner DK, Maynard SK, et al. (2010) Blood fluke exploitation of non-cognate CD4+ T cell help to facilitate parasite development. *PLoS Pathog* 6: e1000892.
10. Takeda K, Akira S (2004) TLR signaling pathways. *Semin Immunol* 16: 3-9.
11. Kumar H, Kawai T, Akira S (2009) Toll-like receptors and innate immunity. *Biochem Biophys Res Commun* 388: 621-625.
12. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. *Int Immunol* 17: 1-14.
13. Hernandez DC, Lim KC, McKerrow JH, Davies SJ (2004) *Schistosoma mansoni*: sex-specific modulation of parasite growth by host immune signals. *Exp Parasitol* 106: 59-61.
14. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(-Delta Delta C(T)) Method. *Methods* 25: 402-408.
15. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, et al. (1999) Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. *Science* 285: 736-739.
16. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, et al. (2000) The repertoire for pattern recognition of pathogens by the innate immune system is


- defined by cooperation between toll-like receptors. *Proc Natl Acad Sci U S A* 97: 13766-13771.
17. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, et al. (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. *Nature* 424: 743-748.
  18. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, et al. (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* 301: 640-643.
  19. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature* 413: 732-738.
  20. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. *Science* 316: 1628-1632.
  21. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, et al. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. *Proc Natl Acad Sci U S A* 98: 9237-9242.
  22. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like receptor recognizes bacterial DNA. *Nature* 408: 740-745.
  23. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, et al. (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. *Nat Immunol* 3: 196-200.
  24. Takeda K, Akira S (2007) Toll-like receptors. *Curr Protoc Immunol* Chapter 14: Unit 14 12.
  25. Kawai T, Akira S (2006) TLR signaling. *Cell Death Differ* 13: 816-825.
  26. Beeson PB (1947) Tolerance to Bacterial Pyrogens : I. Factors Influencing Its Development. *J Exp Med* 86: 29-38.
  27. Greisman SE, Young EJ, Woodward WE (1966) Mechanisms of endotoxin tolerance. IV. Specificity of the pyrogenic refractory state during continuous intravenous infusions of endotoxin. *J Exp Med* 124: 983-1000.
  28. Dalpke AH, Lehner MD, Hartung T, Heeg K (2005) Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. *Immunology* 116: 203-212.
  29. Li CH, Wang JH, Redmond HP (2006) Bacterial lipoprotein-induced self-tolerance and cross-tolerance to LPS are associated with reduced IRAK-1 expression and MyD88-IRAK complex formation. *J Leukoc Biol* 79: 867-875.
  30. Albrecht V, Hofer TP, Foxwell B, Frankenberger M, Ziegler-Heitbrock L (2008) Tolerance induced via TLR2 and TLR4 in human dendritic cells: role of IRAK-1. *BMC Immunol* 9: 69.
  31. Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T (2001) Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. *J Immunol* 166: 5161-5167.
  32. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, et al. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. *J Immunol* 178: 1164-1171.

33. Dillon S, Agrawal S, Banerjee K, Letterio J, Denning TL, et al. (2006) Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. *J Clin Invest* 116: 916-928.
34. Dillon S, Agrawal A, Van Dyke T, Landreth G, McCauley L, et al. (2004) A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. *J Immunol* 172: 4733-4743.
35. Siedlar M, Frankenberger M, Benkhart E, Espevik T, Quirling M, et al. (2004) Tolerance induced by the lipopeptide Pam3Cys is due to ablation of IL-1R-associated kinase-1. *J Immunol* 173: 2736-2745.
36. Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, et al. (2005) A role for fungal  $\beta$ -glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. *J Exp Med* 201: 949-960.
37. Qureshi N, Takayama K, Ribí E (1982) Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of *Salmonella typhimurium*. *J Biol Chem* 257: 11808-11815.
38. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, et al. (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. *Expert Rev Vaccines* 2: 219-229.
39. Field AK, Lampson GP, Tytell AA, Nemes MM, Hilleman MR (1967) Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from *E. coli* infected with MS2 coliphage. *Proc Natl Acad Sci U S A* 58: 2102-2108.
40. Bergquist R, Utzinger J, McManus DP (2008) Trick or treat: the role of vaccines in integrated schistosomiasis control. *PLoS Negl Trop Dis* 2: e244.
41. Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, et al. (2010) Schistosomiasis elimination: lessons from the past guide the future. *Lancet Infect Dis* 10: 733-736.
42. McWilliam HE, Driguez P, Piedrafita D, McManus DP, Meeusen EN (2012) Novel immunomic technologies for schistosome vaccine development. *Parasite Immunol* 34: 276-284.
43. Dean DA (1983) *Schistosoma* and related genera: acquired resistance in mice. *Exp Parasitol* 55: 1-104.
44. Siddiqui AA, Siddiqui BA, Ganley-Leal L (2011) Schistosomiasis vaccines. *Hum Vaccin* 7: 1192-1197.
45. Mountford AP, Shires VL, Anderson S (1998) Interleukin-12 and protective immunity to schistosomes. *Braz J Med Biol Res* 31: 163-169.
46. Mountford AP, Coulson PS, Pemberton RM, Smythies LE, Wilson RA (1992) The generation of interferon-gamma-producing T lymphocytes in skin-draining lymph nodes, and their recruitment to the lungs, is associated with protective immunity to *Schistosoma mansoni*. *Immunology* 75: 250-256.
47. Hogg KG, Kumkate S, Anderson S, Mountford AP (2003) Interleukin-12 p40 secretion by cutaneous CD11c<sup>+</sup> and F4/80<sup>+</sup> cells is a major feature of the innate immune response in mice that develop Th1-mediated protective immunity to *Schistosoma mansoni*. *Infect Immun* 71: 3563-3571.

48. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, et al. (1999) Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. *J Immunol* 162: 3942-3949.
49. Grun JL, Maurer PH (1989) Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. *Cell Immunol* 121: 134-145.
50. Da'Dara AA, Skelly PJ, Walker CM, Harn DA (2003) A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following *Schistosoma mansoni* infection. *Parasite Immunol* 25: 429-437.
51. El Ridi R, Tallima H (2012) Adjuvant Selection for Vaccination against Murine Schistosomiasis. *Scand J Immunol* 76: 552-558.
52. El Ridi RAF, Tallima HAM Novel therapeutic and prevention approaches for schistosomiasis. *Journal of Advanced Research*.
53. Betts CJ, Wilson RA (1998) Th1 cytokine mRNA expression dominates in the skin-draining lymph nodes of C57BL/6 mice following vaccination with irradiated *Schistosoma mansoni* cercariae, but is down-regulated upon challenge infection. *Immunology* 93: 49-54.
54. Klinman DM, Klaschik S, Sato T, Tross D (2009) CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. *Adv Drug Deliv Rev* 61: 248-255.
55. Casella CR, Mitchell TC (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. *Cell Mol Life Sci* 65: 3231-3240.
56. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, et al. (2007) Resiquimod and other immune response modifiers as vaccine adjuvants. *Expert Rev Vaccines* 6: 835-847.
57. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. *Immunol Rev* 239: 178-196.
58. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. *Immunity* 33: 492-503.

**Figure 8. Chronic stimulation of TLR2 with bacterial Pam3CSK4 facilitates *S. mansoni* development in RAG<sup>-/-</sup> mice and results in regulation of pro-inflammatory cytokine gene expression.**


(A) Length of male worms or (B) egg production by schistosome pairs recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment twice a week with either vehicle control, 20 µg Pam3CSK4, or 20 µg zymosan. Groups of 5 mice were used for each experimental condition. . P values for worm lengths were determined using student's T-test with Welch's correction. P values for egg production were determined using the Mann Whitney test. Splenic mRNA levels for (C) IL-1β (D) TNF-α and (E) CCL2 were unchanged while splenic mRNA levels for (F) IFN-γ and (G) IL-6 were down-regulated and (H) splenic IL-10 levels were up-regulated in 6 week schistosome infected RAG<sup>-/-</sup> mice treated twice a week with 20 µg Pam2CSK4. Groups of 5 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined using the Mann Whitney test.



**Figure 9. Restoration of parasite development in RAG<sup>-/-</sup> mice after chronic TLR stimulation is MyD88 dependent.**


(A) Length of male worms recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment twice a week with either vehicle control or 20 µg MPLA. (B) Length of male worms recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment twice a week with either vehicle control or 20 µg CpG. (C) Length of male worms or (D) egg production by schistosome pairs recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment twice a week with either vehicle control or 20 µg guardiquimod. Groups of 5 mice were used for each experimental condition. P values for worm lengths were determined using student's T-test with Welch's correction. P values for egg production were determined using the Mann Whitney test. Splenic mRNA levels for (E) TNF-α and (F) NOS2 were down-regulated while splenic (G) IL-1β (H) CCL2 (I) IFN-γ (J) IL-6 and (K) IL-10 mRNA levels were unchanged in 6 week schistosome infected RAG<sup>-/-</sup> mice treated twice a week with 20 µg guardiquimod. Groups of 5 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined using the Mann Whitney test.






**Figure 10. Chronic TLR-4 signaling via LPS results in downregulated pro-inflammatory gene expression while chronic TLR-3 signaling via poly I:C results in the up-regulation of pro-inflammatory gene expression.**

Splenic mRNA levels for (A) IL-6, (B) IFN- $\gamma$ , and (C) NOS 2 were down-regulated while splenic mRNA expression levels were unchanged for (D) IL-10 in 6 week schistosome infected RAG<sup>-/-</sup> mice treated twice a week with 20  $\mu$ g LPS. Splenic mRNA levels for (E) IL-6 were unchanged while splenic mRNA expression levels were up-regulated for (F) IFN- $\gamma$ , (G) NOS2, and (H) IL-10 in 6 week schistosome infected RAG<sup>-/-</sup> mice treated twice a week with 20  $\mu$ g Poly:Ic. Groups of 5 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined using the Mann Whitney test.



**Figure 11. Chronic TLR signaling does not result in the down-regulation of liver TNF mRNA transcription after egg deposition begins in immunodeficient mice.**

Splenic mRNA levels for (A) TNF and (B) IL-10 were upregulated in the livers of 6 week *S. mansoni* infected RAG<sup>-/-</sup> after chronic LPS stimulation. Splenic mRNA levels for (C) TNF was upregulated while (D) IL-10 transcription levels did not differ from controls in the livers of 6 week *S. mansoni* infected RAG<sup>-/-</sup> after chronic guardaquimod stimulation. Splenic mRNA levels for (E) TNF and (F) IL-10 were upregulated in the livers of 6 week *S. mansoni* infected RAG<sup>-/-</sup> with (G) TNF expression levels correlating with IL-10 transcription levels after chronic Pam3CSK4 stimulation. Splenic mRNA levels for (H) TNF and (I) IL-10 were upregulated in the livers of 6 week *S. mansoni* infected RAG<sup>-/-</sup> with (J) TNF expression levels failing to correlate with IL-10 transcription levels after chronic poly I:C stimulation.



## **Chapter 4**

**IL-1 signaling is not required for innate immune regulation after chronic  
LPS or alum stimulation**

## Introduction

Blood flukes of the genus *Schistosoma* like many parasites have a complex lifecycle involving both a mammalian definitive host and an invertebrate snail intermediate host (find ref). Schistosomes and their definitive hosts (usually human in the case of *S. mansoni*) have co-evolved over 12 million years ago [1]. These blood flukes face the challenge of navigating complex life stage transitions from one host to the next all the while evading the host immune responses. Yet at the same time they also are exploiting host immune factors as signals to coordinate their own development within the definitive host. Worms fail to develop normally in recombination activating gene-deficient ( $\text{RAG}^{-/-}$ ) mice that lack T and B cells, but development is restored after adoptive transfer of  $\text{CD4}^{+}$  T cells [2]. Long-term administration of pathogen associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), a toll-like receptor (TLR-) 4 ligand, to  $\text{RAG}^{-/-}$  mice also restores worm development [3], indicating that innate immune signals are sufficient for parasite development to proceed normally. However, LPS is not normally present in sufficient quantities to provide the stimulus needed to promote innate immune activation raising the question of how during normal infection the innate immune response is activated for the provision of parasitic developmental cues.

The onset of oviposition by *S. mansoni* results in extensive inflammation resulting in pathological changes to the liver and intestines due to granuloma formation around the trapped eggs that has been well reported and described [4-6]. However, before egg deposition begins the development of the worms in the portal vasculature also results in both coagulative necrosis and inflammatory cell infiltration of the liver [7,8]. Through

histological analyses, we have shown that RAG<sup>-/-</sup> mice, unlike their wild type counterparts, fail to develop liver inflammation and necrosis during early infection (Chapter 2 Figure 1). However, restoring liver inflammation in *S. mansoni*-infected RAG<sup>-/-</sup> mice by long-term administration of hepatotoxic drugs restores parasite development (Chapter 2 Figure 2), suggesting that damage associated molecular patterns (DAMPs) released by dying cells, rather than PAMPs, are the physiological activators of the innate immune responses that the parasites require.

As innate immune activation by PAMPs and DAMPs both generate an inflammatory response characterized by the production of the cytokines TNF- $\alpha$  and IL-1 $\beta$  [9,10], we investigated the role of these cytokines in restoring worm development. To accomplish this, we generated RAG<sup>-/-</sup> IL-1 receptor-deficient (IL-1R<sup>-/-</sup>) double knockout mice and used neutralizing antibodies against TNF- $\alpha$  to block TNF signaling in vivo. Here we demonstrate that IL-1 receptor signaling is not required for parasite development to proceed after chronic LPS or alum stimulation. However, it is required for restoration of parasite development to proceed after TNF blockade in RAG mice suggesting that IL-1 signaling is required for regulation of pro-inflammatory responses by neutralizing antibody to TNF.



## Materials and Methods

### Ethics statement:

All animal studies were conducted in accordance with established protocols approved by the USUHS Institutional Animal Care and Use Committee.

### Experimental mice:

RAG-1<sup>-/-</sup> mice on a C57BL/6 background were originally purchased from Jackson laboratory (Bar Harbor, ME) and then bred in-house for experimental use. . RAG-1<sup>-/-</sup> IL-1R<sup>-/-</sup> were generated by crossing C57BL/6 RAG-1<sup>-/-</sup> to C57BL/6 IL-1R<sup>-/-</sup> mice purchased from Jackson laboratory (Bar Harbor, ME). The RAG-1<sup>-/-</sup> IL-1R<sup>-/-</sup> genotype was confirmed via PCR. All mice used in experiments were age matched.

### Parasite parameters:

Mice were infected percutaneously via tail exposure to water containing 160 *S. mansoni* cercariae (Puerto Rican strain) shed from infected *Biomphalaria glabrata* snails. At 6 weeks post infection (p.i.) mice were sacrificed. Worms were perfused from the portal system and immediately fixed in 4% neutral buffered formaldehyde. Male and female worms were counted and photographed at 20x magnification using a Nikon D80 10.0 megapixel digital camera attached to a Zeiss trinocular dissecting microscope. Worm growth was assessed by measuring the length of male worms from digital micrographs Image J software (<http://rsb.info.nih.gov/ij>), as described previously[3]. Only male worms were measured as female growth is dependent upon receiving developmental

cues from pairing with maturing males [11]. Sexual maturation of the parasites was assessed by calculating egg production per worm pair from liver egg burdens, as described previously [3]. Briefly, liver tissue was homogenized and digested in 0.7% trypsin phosphate buffered saline (PBS) solution and the released eggs were counted under a dissecting microscope.

#### Alum and LPS treatment:

RAG-1<sup>-/-</sup> or RAG-1<sup>-/-</sup> IL-1R<sup>-/-</sup> mice were infected with cercariae as described above. Mice received biweekly i.p. injections of Imject Alum (Thermo Scientific, Rockford, IL) at a dose of 1 mg/mouse or ultrapure LPS, *E.coli* 0111:B4 (Invivogen) at a dose of 20 µg/mouse. Control mice received biweekly i.p. injections of PBS without calcium and magnesium. At 6 weeks p.i. mice were sacrificed and parasite parameters were determined as described above.

#### Anti-TNF-α treatment:

RAG-1<sup>-/-</sup> or RAG-1<sup>-/-</sup> IL-1R<sup>-/-</sup> mice were infected with cercariae as previously described. Mice received weekly i.p. injections of Adalimumab (Abbott, Chicago, IL) at a dose of 100 µg/mouse, using PBS without calcium and magnesium as a vehicle. Control mice received weekly i.p. injections of PBS alone. At 6 weeks p.i., mice were sacrificed and parasite parameters were determined as described above.

#### Anti-TNF and LPS treatment

RAG-1<sup>-/-</sup> or RAG-1<sup>-/-</sup> IL-1R<sup>-/-</sup> mice were infected with cercariae as previously described. Mice received weekly i.p. injections of Adalimumab (Abbott, Chicago, IL) at a dose of 100 µg/mouse, using PBS without calcium and magnesium as a vehicle. 24 hours and then 72 hours after receiving adalimumab the mice received i.p. injections of ultrapure LPS, *E.coli* 0111:B4 (Invivogen) at a dose of 20 µg/mouse. At 6 weeks p.i., mice were sacrificed and parasite parameters were determined as described above.

#### RNA isolation, purification, and Real time PCR

RNA was isolated from the spleens and/or livers of wild type or RAG-1<sup>-/-</sup> mice. After removal, tissues were immediately placed in 1 ml RNA-BEE (Tel-Test, Friendswood, Texas), homogenized, snap-frozen in liquid nitrogen and stored at -80°C until isolation of total RNA, following manufacturer's instructions. RNA was further purified following the RNeasy mini protocol for RNA cleanup (Qiagen, Valencia, California). Purified RNA was quantified using a ND-1000 spectrophotometer (Nanodrop, Wilmington, DE). 2 µg of RNA was used for cDNA preparation using a high capacity RNA to cDNA kit (Invitrogen, Grand Island, New York) following manufacturer's instructions. Real time PCR was performed with a MJ Research Chromo4 PTC-200 thermocycler unit (Bio-Rad, Hercules, CA) using Taqman gene expression assays and TaqMan gene expression master mix (Invitrogen) following manufacturer's instructions. Assays for the following mRNAs were performed: *rsp29*, *GAPDH*, *TNF-α*, *IL-1β*, *IL-1α*, *IL-1RA*, *IL-18*, *IL-33*, *CCL2*, and *IFN-γ*. Expression of

genes of interest was normalized to the expression of GAPDH or *rsp29* and fold changes in expression were calculated following the  $2^{-\Delta\Delta CT}$  method [12].

### Statistical analysis

All statistical analyses were performed using GraphPad Prism Inc. version 4.0 software (San Diego, California). Significant differences between two groups were determined using a student's unpaired T-test with Welch's correction for worm lengths or a Mann-Whitney test for egg production. Significant differences between 3 or more groups for worm lengths were determined using ANOVA followed by Tukey's post test. Significant differences between 3 or more groups for egg production were determined using a Kruskal-Wallis test followed by a Dunn's multiple comparison test. *P* values of less than 0.05 were considered significant. 3-5 mice were used per experimental group and each experiment was repeated at least twice.

## Results

### *IL-1 signaling is not required for restoration of parasite development by chronic TLR or inflammasome stimulation*

Previously, we have shown that chronic innate immune stimulation by TLR or inflammasome agonists resulted in the restoration of parasite development in  $RAG^{-/-}$  mice. As  $IL-1\beta$  is a critical downstream mediator of both TLR and inflammasome activation [13,14] we tested whether IL-1 signaling was required for restoration of parasite development by these stimuli. In order to address this question we generated  $RAG^{-/-}IL-1R^{-/-}$  mice by interbreeding  $RAG-1^{-/-}$  and  $IL-1R^{-/-}$  lines. Then groups of  $RAG^{-/-}$ ,  $IL-1R^{-/-}$  and  $RAG^{-/-}IL-1R^{-/-}$  mice were infected to assess parasite development. As previously reported (Chapter 2 Figure 3C and 3D),  $RAG^{-/-}IL-1R^{-/-}$  did not differ from  $RAG^{-/-}$  mice in their ability to support parasite development, with worms recovered from both groups being small in size (Figure 12A) and sexually immature (Figure 12B). Worms from  $IL-1R^{-/-}$  exhibited normal development comparable to that observed in wild type mice, both in terms of parasite growth and egg production, consistent with the conclusion that IL-1R signaling is redundant for parasite development in animals with intact adaptive immunity. Next, we found that IL-1R deletion did not abrogate the ability of chronic LPS or alum administration to restore parasite development, as determined by measurement of parasite size (Figure 12C) and sexual maturation (Figure 12D). Together these data shows that IL-1 signaling is not redundant and nonessential for parasite development, both in immunocompetent mice and immunodeficient mice chronically treated with TLR or inflammasome agonist.

### *Blockade of TNF in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice further stunts parasite development*

As IL-1 signaling was not required for stimulation of restoration of parasite development by LPS or alum, we hypothesized there was functional redundancy between IL-1 $\beta$  and other inflammatory cytokines, especially TNF, as these cytokines share considerable functional overlap in innate immune responses [15]. To test this hypothesis, we utilized an antibody against TNF to block TNF signaling in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice, both in conjunction with and without chronic LPS administration. We found that TNF blockade during pre-patent infection failed to abrogate the ability of LPS administration to restore parasite development in the RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice, as determined by measurement of worm size (Figure 13B) and egg output (Figure 13C). Thus, restoration of parasite development by TLR agonist required neither IL-1 nor TNF signaling. However, we found that TNF blockade in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice that did not receive TLR agonist resulted in significant further impairment of parasite development, with worms recovered from the anti-TNF-treated RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice being significantly smaller in size compared to the worms collected from control RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice that received vehicle alone (Figure 12A). Thus, combined IL-1/TNF blockade in the absence of TLR agonist resulted in even less favorable conditions for parasite development than observed in either RAG<sup>-/-</sup> or RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice.

### *Blockade of TNF in RAG<sup>-/-</sup> mice restores parasite development similar to that of LPS administration*

The finding that anti-TNF suppressed worm development further in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice was in direct contrast to our data showing that anti-TNF was sufficient to restore

parasite development in  $RAG^{-/-}$  mice, presumably due to its ability to restore regulation of pro-inflammatory gene transcription (ref paper 1). As anti-TNF and LPS represent potentially antagonistic treatments, the former promoting control of pro-inflammatory the responses and the latter stimulating them, we tested whether there was any interference between these two treatments in their abilities to restore parasite development in  $RAG^{-/-}$  mice. As reported previously, anti-TNF treatment alone was able to restore parasite growth and egg production in  $RAG^{-/-}$  mice. Simultaneous treatment with both LPS and anti-TNF produced parasites that were indistinguishable in size and egg production from those obtained from animals treated with anti-TNF alone. Thus there was no evidence of an antagonistic or synergistic effects between these two development-promoting treatments.

*Cytokine transcription profiles differ in  $RAG^{-/-}$  and  $RAG^{-/-}IL-1R^{-/-}$  mice treated with anti-TNF*

The divergent results we obtained after TNF blockade in  $RAG^{-/-}$  versus  $RAG^{-/-}IL-1R^{-/-}$  mice suggested that immune responses between these two mouse strains differed after administration of anti-TNF during prepatent infection. To explore this possibility, we examined pro-inflammatory cytokine transcription levels at 24 hours (1 dose anti-TNF), one week (2 doses anti-TNF) and four weeks (5 doses anti-TNF) p.i. in the spleens of  $RAG^{-/-}$  and  $RAG^{-/-}IL-1R^{-/-}$  mice either treated with anti-TNF or with vehicle alone. We found at 24 hours and one week p.i. TNF, IFN- $\gamma$ , IL-1 $\beta$ , IL-18, and IL-33 splenic transcription levels did not differ from vehicle controls in the  $RAG^{-/-}$  and  $RAG^{-/-}IL-1R^{-/-}$  mice that received antibody to block TNF (data not shown). By four weeks p.i., however,

striking differences were seen between the mouse strains. In the  $RAG^{-/-}IL-1R^{-/-}$  mice, where parasite development was further stunted after anti-TNF treatment, we found no differences in the splenic transcription levels of TNF, IL-1 $\beta$ , IL-1 $\alpha$ , IR-1 receptor antagonist, IL-18, IL-33, CCL2, or IFN- $\gamma$  (Figure 4A-H) in the anti-TNF treated animals versus control animals. However, in  $RAG^{-/-}$  mice, splenic transcription levels of TNF, IL-1 $\beta$  and CCL2 (Figure 2C-E chapter 1) as well as, IL-1 receptor antagonist (Figure 5A) were down-regulated at four weeks p.i. in anti-TNF treated animals when compared to vehicle treated controls. Transcription levels for IL-1 $\alpha$ , IL-18, IL-33, and IFN- $\gamma$  in anti-TNF-treated  $RAG^{-/-}$  mice did not differ from controls (Figure 5B-E). These striking differences between the two mouse strains suggests that blocking TNF in  $RAG^{-/-}$  mice induced regulation of several pro-inflammatory genes, and that this anti-TNF-mediated regulation is dependent on IL-1R.



## Discussion

Early schistosome development during acute infection has been known to induce liver inflammation and necrosis in the absence of eggs [8,16]. However, in mice where adaptive immune responses are not intact there is very little in the way of liver inflammation or necrosis during prepatent infection (Chapter 2 figure 1) but induction of cell death by hepatotoxins or supplying exogenous dampers to immunodeficient mice restored parasite development (Chapter 2 figure 2). This provided us with evidence that activation of the innate immune response by inflammasome signaling during normal infection could be a potential mechanism exploited by the parasite for developmental cues. As IL-1 $\beta$  is the hallmark cytokine produced in response to inflammasome activation [17-19] we wanted to further investigate the role it plays in establishing an immune environment conducive for parasite development to proceed. In order to accomplish this goal we bred RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice. Utilizing these mice allowed us to determine the contribution of IL-1 signaling in establishing a regulated immune environment after chronic TLR or inflammasome stimulation. This mouse strain was also useful when used in conjunction with anti-TNF to look at both IL-1 and TNF signaling together as these cytokines have overlapping roles in establishing inflammatory responses.

While intact IL-1 signaling is not required for regulation of pro-inflammatory responses by chronic TLR or inflammasome stimulation it is necessary for TNF blockade to be effective as demonstrated by the failure of parasites to develop in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice after TNF blockade (Figure 13C). As TNF and IL-1 $\beta$  signaling have been shown to

influence each other i.e. the up-regulation of one results in the up-regulation of the other it is not surprising that TNF blockage fails to induce regulation of inflammatory cytokines in IL-1 signaling's absence (Figure 15A-H), and this data taken together indicates that in order for TNF blockade to restore *S. mansoni* development in immunodeficient animals IL-1 signaling must be intact. However, what was surprising was that worms recovered from RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice after TNF blockade were significantly smaller than those recovered from the RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice treated with vehicle control. These results suggest that while TNF blockade failed to result in transcriptional regulation of pro-inflammatory cytokines in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice it never the less had an effect on innate responses creating an even less favorable environment for parasite development to occur in. However, the mechanisms behind how this happens remain to be elucidated.

Administering LPS and alum to RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice during pre-patent infection restored parasite development and suggested that IL-1R signaling was dispensable in creating an appropriate immune environment for parasite development in response to chronic administration of these stimuli. These results support chapter 2's finding specifically that there are multiple mechanisms by which inflammation can be regulated. Chronic LPS stimulation in particular resulted in the transcriptional regulation of not only TNF and IL-1 $\beta$  (Chapter 1, Figure 4) but IL-6 and IFN- $\gamma$  as well (Chapter 2, Figure 10). Taken together this suggests that no single cytokine is responsible for regulating inflammation in response to chronic TLR or inflammasome stimulation. It also highlights again that schistosome development in immunodeficient animals requires the

regulation of pro-inflammatory responses but that the manner in which those responses are regulated is unimportant.


## References

1. Lockyer AE, Olson PD, Ostergaard P, Rollinson D, Johnston DA, et al. (2003) The phylogeny of the Schistosomatidae based on three genes with emphasis on the interrelationships of *Schistosoma* Weinland, 1858. *Parasitology* 126: 203-224.
2. Davies SJ, Grogan JL, Blank RB, Lim KC, Locksley RM, et al. (2001) Modulation of Blood Fluke Development in the Liver by Hepatic CD4<sup>+</sup> Lymphocytes. *Science* 294: 1358-1361.
3. Lamb EW, Walls CD, Pesce JT, Riner DK, Maynard SK, et al. (2010) Blood fluke exploitation of non-cognate CD4<sup>+</sup> T cell help to facilitate parasite development. *PLoS Pathog* 6: e1000892.
4. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, et al. (2007) Immunopathology of schistosomiasis. *Immunol Cell Biol* 85: 148-154.
5. Dunne DW, Pearce EJ (1999) Immunology of hepatosplenic schistosomiasis mansoni: a human perspective. *Microbes Infect* 1: 553-560.
6. Pearce EJ, MacDonald AS (2002) The immunobiology of schistosomiasis. *Nature Reviews Immunology* 2: 499-511.
7. Meleney HE, Moore DV, Most H, Carney BH (1953) The histopathology of experimental schistosomiasis. I. The hepatic lesions in mice infected with *S. mansoni*, *S. japonicum* and *S. haematobium*. *Am J Trop Med Hyg* 1: 263-285.
8. Page CR, 3rd, Etges FJ (1971) Experimental prepatent schistosomiasis mansoni: host mortality and pathology. *Am J Trop Med Hyg* 20: 894-903.
9. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol* 81: 1-5.
10. Schroder K, Tschopp J (2010) The inflammasomes. *Cell* 140: 821-832.
11. Hernandez DC, Lim KC, McKerrow JH, Davies SJ (2004) *Schistosoma mansoni*: sex-specific modulation of parasite growth by host immune signals. *Exp Parasitol* 106: 59-61.
12. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(-Delta Delta C(T)) Method. *Methods* 25: 402-408.
13. Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, et al. (2010) IL-1beta processing in host defense: beyond the inflammasomes. *PLoS Pathog* 6: e1000661.
14. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, et al. (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. *Blood* 113: 2324-2335.
15. Rosenwasser LJ (1998) Biologic activities of IL-1 and its role in human disease. *J Allergy Clin Immunol* 102: 344-350.
16. Meleney HE, Moore DV, Most H, Carney BH (1952) The histopathology of experimental schistosomiasis. I. The hepatic lesions in mice infected with *S. mansoni*, *S. japonicum* and *S. haematobium*. *Am J Trop Med Hyg* 1: 263-285.
17. Ogura Y, Sutterwala FS, Flavell RA (2006) The Inflammasome: First Line of the Immune Response to Cell Stress. *Cell* 126: 659-662.

18. Martinon F, Mayor A, Tschopp J (2009) The Inflammasomes: Guardians of the Body.  
Annual Review of Immunology 27: 229-265.
19. Martinon F, Tschopp J (2005) NLRs join TLRs as innate sensors of pathogens.  
Trends Immunol 26: 447-454.

**Figure 12. IL-1 receptor signaling is not required for restoration of parasite development in immunodeficient mice after chronic inflammasome or TLR stimulation.**




Parasites development was normal in IL-1R<sup>-/-</sup> mice. (A) Length of male worms recovered and (B) egg production by schistosome pairs recovered from RAG<sup>-/-</sup>, RAG<sup>-/-</sup>IL-1R<sup>-/-</sup>, and IL-1R<sup>-/-</sup> mice at 6 weeks p.i.. Parasite development was restored after chronic TLR4 or NALP3 inflammasome stimulation in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> during prepatent schistosome infection. (C) Length of male worms recovered and (D) egg production by schistosome pairs recovered from RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice at 6 weeks p.i. after treated twice a week either vehicle control 20 µg LPS or 1 mg alum. Groups of 5 mice were used for each experimental condition. P values for worm lengths were determined using an ANOVA followed by a Tukey's post test. P values for egg production were determined using the Kruskal Wallis test followed by a Dunn's multiple comparison post test.



**Figure 13. Neither TNF nor IL-1R signaling are required for restoration of parasite development in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice after chronic TLR stimulation.**


(A) Length of male worms recovered and (B) egg production by schistosome pairs recovered from RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice at 6 weeks p.i. after treatment once a week with 100 µg anti-TNF-α as well as twice a week with 20 µg LPS and as compared to vehicle treated controls. (C) Length of male worms from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment once a week with 100 µg anti-TNF-α. Groups of 5 mice were used for each experimental condition. P values for worm lengths were determined using student's T-test with Welch's correction. P values for egg production were determined using the Mann Whitney test.






**Figure 14. TNF blockade alone is sufficient for restoration of parasite development in RAG<sup>-/-</sup> mice after chronic TLR stimulation.**

Length of male worms (A) and (B) egg production by schistosome pairs recovered from RAG<sup>-/-</sup> mice at 6 weeks p.i. after treatment once a week with 100 µg anti-TNF-α or after treatment once a week with 100 µg anti-TNF-α as well as twice a week with 20 µg LPS as compared to vehicle treated controls. Groups of 5 mice were used for each experimental condition. P values for worm lengths were determined using an ANOVA followed by a Tukey's post test. P values for egg production were determined using the Kruskal Wallis test followed by a Dunn's multiple comparison post test.




**Figure 15. TNF blockade does not result in changes to splenic inflammatory cytokine gene expression in RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice.**

Splenic mRNA levels for (A) IL-1 $\beta$  (B) TNF- $\alpha$  (C) IL-1 $\alpha$  (D) IL-1RA (E) IL-18 (F) IL-33 (G) CCL2 and (H) IFN- $\gamma$  were unchanged in 4 week schistosome infected RAG<sup>-/-</sup>IL-1R<sup>-/-</sup> mice after treatment once a week with 100  $\mu$ g anti-TNF- $\alpha$ . Groups of 5 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined using the Mann Whitney test.



**Figure 16. TNF blockade results in downregulated splenic IL-1 receptor antagonist (IL-1RA) in RAG<sup>-/-</sup> mice.**

Splenic mRNA levels for (A) IL-1RA were down-regulated while they remained unchanged for (B) IL-1 $\alpha$ , (C) IL-18, (D) IL-33, and (F) IFN- $\gamma$  in 4 week schistosome infected RAG<sup>-/-</sup> mice after treatment once a week with 100  $\mu$ g anti-TNF- $\alpha$ . Groups of 5 mice were used for each experimental condition. Mean values are represented by horizontal bars. P values were determined using the Mann Whitney test.



## **Chapter 5**

### **Summary and Future Directions**



## Dissertation Summary

Having established that the role of CD4<sup>+</sup> T cells in facilitating schistosome development is indirect and mediated via provision of T cell help for innate responses, the goal of the work presented here was to gain a better understanding into how innate immune responses support the development of schistosomes in RAG<sup>-/-</sup> mice. The principal questions we wished to address were (i) how does *S. mansoni* activate the innate immune response in order to facilitate its own development, and (ii) what elements of the innate immune response are required for schistosome development to occur. Having shown that chronic administration of a TLR4 agonist could facilitate parasite development, we sought to identify other and perhaps more physiologically relevant stimuli of innate immune responses that could mediate the same effects. We provided histological evidence that hepatic responses to the developing parasite were fundamentally different in RAG<sup>-/-</sup> and wild type mice, with RAG<sup>-/-</sup> mice showing little evidence of the hepatocellular necrosis and inflammatory infiltration characteristic of infection in wild type mice. Furthermore, we were able to show that by administering MSU, a product of cell death, we were able to again restore parasite development in RAG<sup>-/-</sup> mice, suggesting that in immunocompetent mice, cell death and the resultant inflammation may be important in determining the progress of parasite development. Finally, we surveyed the breadth of innate stimuli and immune modulators that either restored or impeded *S. mansoni* development and determined that improved parasite development correlated with regulation of innate pro-inflammatory responses. Among the immune modulators that restored parasite development was IL-4, a type 2 cytokine

produced by adaptive responses to pre-patent infection in immunocompetent hosts. This finding suggests that, by virtue of their ability to regulate pro-inflammatory processes, Th2 responses may be associated with schistosome development in immunologically intact hosts.

### **Timeline for *S. mansoni* development in the context of the host immune response**

The skin is the first major site for schistosome development in the definitive host, with the transformation of cercariae into schistosomula during successful invasion involving dramatic anatomical, physiological, and biochemical changes [1], including the loss of the cercarial tail, shedding of the glycocalyx, formation of the tegument, and the release of excretory secretory (ES) products from acetabular glands [2,3]. Migration of the parasites through skin via the epidermis, basement, membrane and dermis, with the eventual penetration of a dermal blood vessel or a lymphatic vessel, is estimated to take approximately 3 days [2,4]. In the circulation, schistosomula arrive in the lungs, this point in development being described as stage 1 or the “lung form” [5,6]. The parasites reside in the pulmonary capillaries, increasing 4 fold in length and with a proportionate decrease in diameter [7], these changes in morphology accomplished by redistribution of already existent cells and tissues, with no increases in mass [8] and no mitosis [6]. Migration from the lungs to the liver begins approximately 7 days post infection, with the schistosomula contracting back to their original skin morphology upon arrival in the portal circulation. Ingestion of blood begins, and is accompanied by increased O<sub>2</sub> usage

and lactic dehydrogenase activity [7]. Stages 2-6 of development take place in liver venules. Stage 2 is defined by the development of the gut at 15 days p.i. Stage 3 is defined by the development of the testes of male worms and uterus of females worms at 21 days p.i. Stage 4 is defined by the onset of gametogeny at 28 days p.i. Stage 5 is defined by the start of egg shell formation 30 days p.i. The climax of schistosome development, stage 6, is defined by the onset of oviposition at 34-35 days p.i. [5,6]. As the majority of parasite growth and development take place in hepatic venules from approximately 1 week p.i. to 5 to 6 weeks p.i. this is the time frame in which the immune responses could provide critical developmental cues.


The immune responses generated early in infection in immunologically intact hosts, prior to the onset of egg production, have been described as weak Th1 like responses [9]. However, Th2 responses have also been shown to occur early in infection. Schistosomula ES components inhibit inflammatory cell recruitment, induce T-cell apoptosis and elicit human keratinocytes to produce IL-10 [2,10-13], thus potentially contributing to the overall anti-inflammatory phenotype of the host response during pre-patent infection. Migration of *S. japonicum* schistosomula through the lung capillaries also resulted in innate immune wound healing responses characterized by RELM- $\alpha$  production [14]. By four weeks post infection, IgE antibodies are produced to a *S. mansoni* cysteine protease (SmCB1) with the help of CD4<sup>+</sup> T-cells and IL-4, indicating that Th2 responses do occur early in infection [15] and supporting previous reports that cysteine proteases may be pro- Th2-inducing antigens [16]. Schistosome hemozoin, also known as worm pigment, is the by-product of hemoglobin degradation and has also been shown to induce markers of alternative macrophage activation in hepatocytes [17]. We

have found worm pigment in liver sections as early as 3 weeks p.i. in wild type mice (data not shown). Schistosome glycans expressed from the beginning of infection onwards [18,19] also elicit strong Th2 responses [19] and drive alternative activation of macrophages [20]. Thus, there are multiple potential mechanisms by which schistosomes might drive the Th2 polarization of CD4<sup>+</sup> T cell responses during early infection. We therefore propose the following model (Figure 17) of how Th2 responses might be induced during infection and how these responses could potentially create an immunoregulated environment permissive for parasite development.


**Figure 17. Potential model highlighting early *S. mansoni* and host immune interactions during prepatent infection**

Parasite antigens interact with antigen presenting cells (APCs) (1). APCs in turn interact with CD4<sup>+</sup> T-cells resulting in a Th2 response (2). The resulting Th2 responses create an environment permissive for parasite development (3).


1.



2.



3.



**Creation of permissive environment for parasite development**

1. de Oliveira Fraga LA, Lamb EW, Moreno EC, Chatterjee M, Dvorak J, et al. Rapid induction of IgE responses to a worm cysteine protease during murine pre-patent schistosome infection. BMC Immunol 11: 56.
2. Truscott M, Evans DA, Gunn M, Hoffmann KF (2013) Schistosoma mansoni hemozoin modulates alternative activation of macrophages via specific suppression of Retnla expression and secretion. Infect Immun 81: 133-142.
3. Faveeuw C, Mallevaey T, Paschinger K, Wilson IB, Fontaine J, et al. (2003) Schistosome N-glycans containing core alpha 3-fucose and core beta 2-xylose epitopes are strong inducers of Th2 responses in mice. Eur J Immunol 33: 1271-1281.

## Immunological Redundancy in Parasite Development

A recurring theme in all of our studies is that there are likely multiple immunological pathways by which schistosomes can obtain the conditions necessary for development. While schistosomes have been shown to respond to human cytokines such as TGF- $\beta$  [21] and TNF [22] these signaling pathways are evolutionarily ancient and conserved among numerous eukaryotic organisms [23], suggesting that a single host cytokine alone is not responsible for restoration of parasite development in immunodeficient mice. Furthermore, with regard to the support of parasite development by adaptive responses, IL-4 is clearly not the only host factor capable of creating an environment that favors *S. mansoni* development, as parasite development is normal in mice where IL-4 or IL-4 receptor signaling is blocked [24-26]. The diverse transcription profiles generated in response to chronic TLR or inflammasome activation in RAG<sup>-/-</sup> mice also demonstrate that regulation of pro-inflammatory responses occurs in variety of ways. Importantly, there is little or no IL-4 produced in the absence of CD4<sup>+</sup> cells, and thus chronic administration of TLR and inflammasome agonists in RAG<sup>-/-</sup> does not result in regulation by inducing type 2 responses. Rather, we hypothesize that other, less clearly defined immunoregulatory states are induced under these conditions, perhaps analogous to the regulatory states found in other disease conditions such as cancer [27,28].

As both type 2 and immunoregulatory states all suffice to restore parasite development, this raises the question of what precisely schistosomes obtain from these immunological milieus. One possibility is that some destructive anti-schistosome effector mechanism is kept in check by regulatory responses. One possible candidate for such a

mechanism is the production of NO, which was previously shown to be an important correlate of immunity in animals vaccinated with irradiated cercariae. Another alternative is that the wound healing and tissue remodeling processes supported by these responses are in some way necessary for parasite development. One possible scenario is that developing schistosomes in the hepatic venules require a certain amount of niche remodeling to occur, perhaps in the form of vessel expansion to accommodate the growing parasite, and thus the angiogenesis component of wound healing may be the critical aspect of these responses for schistosomes. Inhibitors of angiogenesis have been well characterized as cancer treatments [29,30] and could be administered during early *S. mansoni* infection in wild type mice in order to further characterize the role of angiogenesis during early *S. mansoni* development. Numerous inhibitors for angiogenesis have been described in the literature, including antibodies against vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) [30,31] as well as small molecule VEGFR tyrosine kinase inhibitors [30]. The VEGF family is complex and includes 6 secreted glycoproteins and 5 receptors, making single antibody therapy difficult for cancer treatment [32]. Small molecular tyrosine kinase inhibitors make a more attractive option to block angiogenesis during early *S. mansoni* development. However, drugs like sorafenib have been shown to also induce reactive oxygen species (ROS) in endothelial cells [33] and to restore classical macrophage polarization and natural killer cell activation in hepatocellular carcinoma microenvironments [34]. Therefore the broad effects of tyrosine kinase inhibitors could confound data interpretation.

Yet another possibility is that changes in cell metabolism associated with each of these immunoregulatory states may be required in order for developing schistosomes to



meet their trophic requirements. Inflammation and immunoregulation initiate dramatic changes in cell metabolism, promoting aerobic glycolysis and increasing the availability of ATP and various precursor molecules for fatty acid and nucleotide synthesis. As parasites, schistosomes are auxotrophic for a variety of host molecules, ranging from cholesterol and fatty acids to purines, and indeed, their genomes are replete with genes that likely facilitate acquisition of these molecules from the host. Glycolysis inhibitors have been widely studied in cancer biology due to increased aerobic glycolysis occurring in tumors [35]. Two potential inhibitors that could be utilized used to test the importance of host glycolysis for schistosome development in wild type mice are 2-deoxy-glucose (2-DG) [36] and 3-bromopyruvate [37]. 2-DG inhibits glycolysis at the step of glucose phosphorylation by hexokinase, hexokinase instead phosphorylating 2-DG and resulting in the accumulation of 2-DG-P [35]. 3-bromopyruvate also interferes with glycolysis by inhibiting hexokinase activity [37]. However, both of these drugs also interfere with other aspects of cellular metabolism, resulting in cell death by other mechanisms besides ATP depletion [35], and complicating the interpretation of any effects these compounds may have on parasite development.

### **Host cells required for parasite development**

M2 macrophages are an attractive candidate for being a host factor co-opted by schistosomes and future work should focus on defining the role this cell type plays in early schistosome development. The critical role M2 macrophages play in controlling


egg induced pathology has been well characterized [38-41], but their role in shaping schistosome-driven immune responses before egg deposition commences remains to be elucidated. M2 macrophage cell profiles have been well characterized by flow cytometry [42] and these tools could be utilized to characterize macrophage populations in the spleens and livers of wild type and RAG<sup>-/-</sup> mice early during pre-patent infection. M2 macrophage populations can also be adoptively transferred into RAG<sup>-/-</sup> mice during pre-patent infection, with the goal of creating an immune environment permissive for parasite development. Finally, schistosome glycans such as Lacto-N-neofucopentaose III have been shown to drive Th2 immune responses in experimental schistosome infection by inducing an alternative activation state in APCs [43,44], including macrophages [20]. Glycans may therefore be an ideal worm-derived candidate to drive type 2 responses in RAG<sup>-/-</sup> mice during prepatent infection, again with the goal of creating an immune environment permissive for parasite development.

While M2 macrophage populations are attractive candidates for shaping regulated immune states during schistosome infection, other innate cell populations also have been shown to play important roles in inducing Th2 responses during *S. mansoni* infection. Dendritic cells (DCs) in particular have been shown to be important in driving Th2 responses after exposure to either cercarial ES products [45] or egg antigens [43]. The Th2-inducing cytokine thymic stromal lymphopoietin (TSLP) has been shown to be an important cytokine involved in both the maintenance and polarization of Th2 responses by DCs [46,47]. Although parasite development was normal in TSLPR<sup>-/-</sup> mice [48], TSLP and IL-4 are host factors that could potentially be co-opted by schistosomes to provide developmental cues. Provision of exogenous TSLP to RAG<sup>-/-</sup> mice would test whether

TSLP can induce an environment conducive to parasite development, as we established for IL-4. If TSLP administration restored parasite development in  $RAG^{-/-}$  mice, further experiments could be conducted using  $RAG^{-/-}$  common gamma ( $\gamma c$ ) chain knockout ( $\gamma c^{-/-}$   $RAG^{-/-}$ ) mice to tease out the contribution of type 2 innate lymphoid cells (ILC2s) in this process, as this cell population also produces Th2 cytokines in response to TSLP [49]. However, ILC2s are unlikely to play a non-redundant role in restoration of parasite development. Because we previously found that LPS could restore parasite development in  $\gamma c^{-/-}$   $RAG^{-/-}$  mice (Figure 19). These findings suggest that  $\gamma c$  chain cytokine-dependent innate cells are not required for the regulation of innate immune responses critical for parasite development to occur.

**Figure 18. Chronic stimulation of TLR4 with bacterial LPS facilitates *S. mansoni* development in  $\gamma\text{c}^{-/-}\text{RAG}^{-/-}$  mice.**

(A) Length of male worms recovered from  $\gamma\text{c}^{-/-}\text{RAG}^{-/-}$  mice at 6 weeks p.i. after treatment twice a week with either vehicle control or LPS. Groups of 5 mice were used for each of the experimental conditions. P values for worm lengths were determined using student's T-test with Welch's correction.



## Concluding Remarks

Davies and McKerrow suggested that delaying development in immunodeficient hosts could provide a selective advantage to the parasite allowing it to prolong its survival [50]. The work put forth in this dissertation adds further support to what Davies and McKerrow originally proposed. It is intriguing to think that *S. mansoni* might have evolved to recognize host immune regulation early in develop before sexual maturation in order to ensure its long term survival. Fully developed worms can live in the mesenteric vasculature for years [51] releasing eggs to ensure that their genes survive. If they are in the right immune environment i.e. one where there is appropriate granuloma formation to ensure the passage of the egg into the lumen of the intestine and to protect the host from the egg toxins as well there is a better chance of this occurring. If excessive pathology due egg production can be mitigated this allows the host to survive and again increases the chances of the eggs escaping to be passed with the feces and continue the life cycle. Thus, host immune responses as developmental cues makes evolutionary sense and gives the parasite a selective advantage, providing an elegant mechanism to ensure their own survival. A better understanding of early host schistosome interactions could provide useful targets for disrupting schistosome infections by improved treatments or vaccine development.

## References

1. Warren KS (1982) Schistosomiasis: host-pathogen biology. *Rev Infect Dis* 4: 771-775.
2. Jenkins SJ, Hewitson JP, Jenkins GR, Mountford AP (2005) Modulation of the host's immune response by schistosome larvae. *Parasite Immunol* 27: 385-393.
3. Skelly PJ, Shoemaker CB (2000) Induction cues for tegument formation during the transformation of *Schistosoma mansoni* cercariae. *Int J Parasitol* 30: 625-631.
4. He Y-X, Chen L, Ramaswamy K (2002) *Schistosoma mansoni*, *S. haematobium*, and *S. japonicum*: early events associated with penetration and migration of schistosomula through human skin. *Experimental Parasitology* 102: 99-108.
5. Clegg JA (1959) Development of sperm by *Schistosoma mansoni* cultured in vitro. *Bull Res Councl Isr Sect E Exp Med* 8E: 1-6.
6. Clegg JA (1965) In vitro Cultivation of *Schistosoma mansoni*. *Exp Parasitol* 16: 133-147.
7. Wilson RA (2009) The saga of schistosome migration and attrition. *Parasitology* 136: 1581-1592.
8. Lawson JR, Wilson RA (1980) Metabolic changes associated with the migration of the schistosomulum of *Schistosoma mansoni* in the mammal host. *Parasitology* 81: 325-336.
9. Pearce EJ, MacDonald AS (2002) The immunobiology of schistosomiasis. *Nature Reviews Immunology* 2: 499-511.
10. Ramaswamy K, Kumar P, He YX (2000) A role for parasite-induced PGE2 in IL-10-mediated host immunoregulation by skin stage schistosomula of *Schistosoma mansoni*. *J Immunol* 165: 4567-4574.
11. Angeli V, Faveeuw C, Roye O, Fontaine J, Teissier E, et al. (2001) Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. *J Exp Med* 193: 1135-1147.
12. Herve M, Angeli V, Pinzar E, Wintjens R, Faveeuw C, et al. (2003) Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion. *Eur J Immunol* 33: 2764-2772.
13. Chen L (2002) Skin-stage *Schistosomula* of *Schistosoma mansoni* Produce an Apoptosis-inducing Factor That Can Cause Apoptosis of T Cells. *Journal of Biological Chemistry* 277: 34329-34335.
14. Burke ML, McGarvey L, McSorley HJ, Bielefeldt-Ohmann H, McManus DP, et al. (2011) Migrating *Schistosoma japonicum* schistosomula induce an innate immune response and wound healing in the murine lung. *Mol Immunol* 49: 191-200.
15. de Oliveira Fraga LA, Lamb EW, Moreno EC, Chatterjee M, Dvorak J, et al. Rapid induction of IgE responses to a worm cysteine protease during murine pre-patent schistosome infection. *BMC Immunol* 11: 56.
16. Sokol CL, Barton GM, Farr AG, Medzhitov R (2008) A mechanism for the initiation of allergen-induced T helper type 2 responses. *Nat Immunol* 9: 310-318.
17. Truscott M, Evans DA, Gunn M, Hoffmann KF (2013) *Schistosoma mansoni* hemozoin modulates alternative activation of macrophages via specific suppression of Retnla expression and secretion. *Infect Immun* 81: 133-142.

18. Meyer S, van Liempt E, Imberty A, van Kooyk Y, Geyer H, et al. (2005) DC-SIGN mediates binding of dendritic cells to authentic pseudo-LewisY glycolipids of *Schistosoma mansoni* cercariae, the first parasite-specific ligand of DC-SIGN. *J Biol Chem* 280: 37349-37359.
19. Faveeuw C, Mallevaey T, Paschinger K, Wilson IB, Fontaine J, et al. (2003) Schistosome N-glycans containing core alpha 3-fucose and core beta 2-xylose epitopes are strong inducers of Th2 responses in mice. *Eur J Immunol* 33: 1271-1281.
20. Atochina O, Da'dara AA, Walker M, Harn DA (2008) The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo. *Immunology* 125: 111-121.
21. Loverde PT, Osman A, Hinck A (2007) *Schistosoma mansoni*: TGF-beta signaling pathways. *Exp Parasitol* 117: 304-317.
22. Oliveira KC, Carvalho ML, Venancio TM, Miyasato PA, Kawano T, et al. (2009) Identification of the *Schistosoma mansoni* TNF-Alpha Receptor Gene and the Effect of Human TNF-Alpha on the Parasite Gene Expression Profile. *PLoS Negl Trop Dis* 3: e556.
23. Wilson RA (2012) The cell biology of schistosomes: a window on the evolution of the early metazoa. *Protoplasma* 249: 503-518.
24. Brunet LR, Finkelman FD, Cheever AW, Kopf MA, Pearce EJ (1997) IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis. *J Immunol* 159: 777-785.
25. Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, et al. (2004) Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. *Immunity* 20: 623-635.
26. Hoffmann KF, Cheever AW, Wynn TA (2000) IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. *J Immunol* 164: 6406-6416.
27. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. *Curr Opin Immunol* 22: 231-237.
28. Porta C, Riboldi E, Sica A (2011) Mechanisms linking pathogens-associated inflammation and cancer. *Cancer Lett* 305: 250-262.
29. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol* 23: 1011-1027.
30. Takahashi S (2011) Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. *Biol Pharm Bull* 34: 1785-1788.
31. Kim KJ, Li B, Winer J, Armanini M, Gillett N, et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature* 362: 841-844.
32. Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, et al. (2011) A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. *J Natl Compr Canc Netw* 9: 414-427.



33. Coriat R, Nicco C, Chereau C, Mir O, Alexandre J, et al. (2012) Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. *Mol Cancer Ther* 11: 2284-2293.
34. Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, et al. (2013) Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells. *Hepatology*.
35. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. *Oncogene* 25: 4633-4646.
36. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, et al. (2004) 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. *Cancer Res* 64: 31-34.
37. Shoshan MC (2012) 3-Bromopyruvate: targets and outcomes. *J Bioenerg Biomembr* 44: 7-15.
38. Herbert DR, Orekov T, Roloson A, Ilies M, Perkins C, et al. (2010) Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis. *J Immunol* 184: 6438-6446.
39. Chen F, Liu Z, Wu W, Rozo C, Bowdridge S, et al. (2012) An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. *Nat Med* 18: 260-266.
40. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, et al. (2009) Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. *PLoS Pathog* 5: e1000371.
41. Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF, et al. (2006) The IL-21 receptor augments Th2 effector function and alternative macrophage activation. *J Clin Invest* 116: 2044-2055.
42. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, et al. (2011) Local Macrophage Proliferation, Rather than Recruitment from the Blood, Is a Signature of TH2 Inflammation. *Science* 332: 1284-1288.
43. Thomas PG, Carter MR, Atochina O, Da'Dara AA, Piskorska D, et al. (2003) Maturation of dendritic cell 2 phenotype by a helminth glycan uses a Toll-like receptor 4-dependent mechanism. *J Immunol* 171: 5837-5841.
44. Harn DA, McDonald J, Atochina O, Da'dara AA (2009) Modulation of host immune responses by helminth glycans. *Immunol Rev* 230: 247-257.
45. Jenkins SJ, Mountford AP (2005) Dendritic cells activated with products released by schistosome larvae drive Th2-type immune responses, which can be inhibited by manipulation of CD40 costimulation. *Infect Immun* 73: 395-402.
46. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, et al. (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat Immunol* 3: 673-680.
47. Wang YH, Ito T, Homey B, Watanabe N, Martin R, et al. (2006) Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. *Immunity* 24: 827-838.
48. Ramalingam TR, Pesce JT, Mentink-Kane MM, Madala S, Cheever AW, et al. (2009) Regulation of helminth-induced Th2 responses by thymic stromal lymphopoietin. *J Immunol* 182: 6452-6459.

49. Mjosberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, et al. (2012) The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. *Immunity* 37: 649-659.
50. Davies SJ, McKerrow JH (2003) Developmental plasticity in schistosomes and other helminths. *International Journal for Parasitology* 33: 1277-1284.
51. Pearce EJ, MacDonald AS (2002) The immunobiology of schistosomiasis. *Nat Rev Immunol* 2: 499-511.